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PREFACE 
At Tartu University, the neuro-psychopharmacological 
research, including that done by the teams of pharmacology, 
psychiatry and biochemistry departments, has been going on 
for 25 years already. The laboratory of Psychopharmacology 
both for experimental and clinical research was established 
in 1967« At Tartu University, the symposia on neuro-psycho-
pharmacology have been performed regularly in every 2-3 
years. The transactions (in Russian) on special fields of 
psychopharmacologlcal research (GABAergic drugs, neurolep­
tics, novel psychoactive compounds, etc.) have also been 
published. The present publication is our first English edi­
tion, and it deals with the molecular mechanisms of psycho­
tropics. This problem has been investigated at the Depart­
ment of Pharmacology during past 8 years. The first volume 
of this series "Molecular Mechanisms of psychotropics" was 
issued in 1987 (Acta et comm. Univereltatis Tartuensis, 
N 766). 
In this volume, the papers are mostly devoted to benzo­
diazepine receptors (binding sites in the brain and in peri­
pheral tissues), to functional changes under stress and 
GABAerglcs. The other topic deals with D1 and D2 receptors, 
neuroleptic and cholecystoklnin interactions, Including the 
adaptation problem in pharmacology. We hope that this volu­
me will be of use and value tor those who are directly con­
cerned with fundamental research in molecular pharmacology. 
Lembit H. Allikmets 
Professor and Chairman 
Department of Pharmacology 
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PERIPHERAL-TYPE BBHZODMZBPIHB BINDING SITES: 
FUNCTIONAL RECEPTORS OR ACCEPTORS 
L. Rägo, V. Saano* M. Rätyf and A. Adojaan 
Department of Pharmacology, Tartu State Uni­
versity, Tartu, Estonia, USSR, and Department 
of Pharmacology and Toxicology* University of 
Kuopio, Kuopio, Finland 
Abstract: 
The eentral-type benzodiazepine (BZ) binding 
site, often referred to aa the BZ receptor, is an in­
tegral part of the GABAA receptor-chloride channel in 
the mammalian CNS by means of which benzodiazepine 
and nonbenzodiazepine compounds produce either posi­
tive or negative allosteric modulation of the channel 
gaiting function with subsequent characteristic phar­
macological effects. So far BZ receptors have not been 
established outside the CNS. In the contrary, the pe­
ripheral-type BZ binding sites are widely distributed 
in many organs and tissues outside the CNS but they 
can be found also in the CNS. Although the peripheral 
type BZ binding sites have been known for ten years 
already, the main efforts of the researchers were con­
centrated on central-type BZ binding sites. However« 
during the past few years considerable progress has 
been made in clarifying the multiple functions and 
properties of peripheral-type BZ binding sites.In our 
review the distribution, development, physiological 
regulation and functions, as well as the problem of 
possible exogeneous and endogeneous ligands of peri­
pheral-type BZ recognition sites are discussed to de­




1,4-Benzodiazepines (BZ) belong to the moat widely uaed 
drugs. They are primarily used as anxiolytic», being also 
effective »8 anticonvulsants, hypnotics, and muscle relax­
ants. Their site of action, specific benzodiazepine (BZ) re­
ceptors, was discovered a decade ago (69,95). Ehen the bind­
ing of tritiated diazepam on various tissues in vitro was 
studied, diazepam appeared to^attach saturably, specifically 
and with a high affinity also to the tissues not belonging 
to the central nervous system (22). This binding to the pe­
ripheral BZ binding sites has been demonstrated also in vi­
vo (11). The binding sites in the peripheral organs, however, 
differ in several respects from those in the CHS, and many 
BZ compounds show selectivity in their binding to these two 
receptor groups. 
Until recently, it was considered that the binding of 
the peripheral recognition sites would not, unlike that to 
the central receptors, be stereospecific (104). This, obvi -
ously, is the case with cultured erytholeukemia cells, while 
binding to several rat tissues, as well as to human granulo­
cytes shows definite stereospecificity (19,33). 
The molecular structure of BZ compounds determines the 
affinity of each compound. For a benzodiazepine compound to 
have a high affinity for the peripheral site, fcethyl substi-
tuent must be in position 1 (104). In contrast, clonazepam 
lacks the substituent in position 1, and it has ä very high 
affintiy to the central receptor, but it only very weakly 
displaces the specific ligands from the peripheral BZ bind­
ing sites. On the other hand, Ro 5-4864, a chloro-substitu -
ted diazepam, displaces diazepam from peripheral BZ recogni­
tion sites approximately 30 thousand times more potently 
than from the central BZ receptors (22). Besides 1,4 -benzo­
diazepines some isoquinoline carboxamides, such as К 11195, 
have also high affinity for the peripheral BZ binding sites 
(14). However, a great part of the research into the periphe­
ral BZ binding sites has been carried out using tritiated 
diazepam or flunitrazepam, which nonselectively bind both to 
central and peripheral binding sites (22,78). The availabi -
lity of such peripheral BZ receptor ligands as Ro 5-4864 (23 
90) and PK 11195 (14) has stimulated research into these 
binding sites. 
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Pig. 1. Compounds with a high affinity for the periphe­
ral-type benzodiazepine binding sites 
(Ro 5-4864, diazepam, PK 11195). Clonazepam, B-
carfcolines such as 3-carboethoxy-ß-carboline 
and imidazobenzodiazepine Ro 15-1788 bind se­
lectively to the central-type receptor only. 
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2. DISTRIBUTION OP PERIPHERAL-TYPE BINDING SITES. 
Originally the classification of BZ receptors was made 
according to the localization of receptors in various organs. 
While the central BZ receptors are situated in the neuronal 
tissue only, the peripheral BZ binding sites occur in seve­
ral tissues, e.g. in heart (28,42,100), lungs and adrenals 
(22,31), in kidneys (3,8,30,31,42,100), in testes, liver, 
spleen, the epithelian tissue of nose, tongue and in the sa­
livary glands (31), in human placenta (34), lymphocytes (66) 
mast cells (98), granulocytes (19) and platelets (15,103)• So 
far only few muscles have been investigated in the case of 
the human: iris/ciliary-body preparations (111) and myomet­
rium (81) both contain high affinity peripheral-type BZ bind­
ing sites. Also the rat diaphragm and the guinea-pig ileal 
muscle contain these binding sites (48,110), although the 
striated muscle and gastrointestinal tissues have been said 
to lack any peripheral BZ receptors (1). 
The peripheral-type BZ binding sites are situated in 
brain (3,14^1,42,56,89) and in spinal cord (29,113). The ol­
factory bulb (90) and the pineal gland (54,75,108) show par­
ticularly high density of these recognition sites. In gene -
ral, their density in the neuronal tissues is lewer'tlanthat 
in peripheral organs, but in several animal species as well 
as in man the distribution of the peripheral-type BZ binding 
sites in brain shows a distinctive pattern different frem tbe 
relative heterogeneity of the distribution of the central -
type binding sites (1,42). Autoradiographic loaalieation of 
peripheral BZ receptors has shown that specific ^H-Ro 5-4864 
binding sites can also be observed in the choroid plexus and 
ependyma cells within the rat brain (42) .Intrastriatal injec­
tion of excitotoxic compounds has been demonstrated to pro­
voke a dose-dependent increase in. the levels of peripheral BZ 
binding sites with the following potency order: kainate > 
(RS)-#< -amino-3-hydroxy-5-methyl-4-isoxazolopropionic acid 
(AMPA)>N-methyl-D-aspartate (NMDA)>quisqualate (9). The au­
thors concluded that peripheral BZ binding sites constitute 
a more sensitive indirect index of neuronal damage than neu­
ronal enzymes, choline acetyltransferase or glutamate decar­
boxylase. Although intrastriatal kainate is known to cause 
neuronal damage and glial proliferation, a further characte­
2 9 
rization of the localization of peripheral BZ binding sites 
to different types of glia is necessary. Similarly to ihe 
experimental neuronal damages the peripheral-type BZ bind­
ing sites appear to be elevated also in the case of senile 
dementia of the Alzheimer type and Huntington's disease (72, 
91). 
However, recent autoradiographic studies in human brain 
with %-PK 11195 suggest a neuronal rather than glial loca­
lization of peripheral BZ binding sites found in forebrain 
structures and the localization was not limited to any func­
tional system, nor did it resemble any previously described 
transmitter system (32). 
The tissues that contain high densities of the periph­
eral BZ binding sites produce their energy by oxidative 
phosphorylation. For example, in kidneys the highest densi-
sities of these receptors are in the neighbourhood of the 
ascending part of the loop of Henle and the collecting ducts 
- these structures contain the highest amount of mitochond­
ria. Also the oytochromal activity is the highest in the a-
reas which contain the highest densities of peripheral 3Z 
binding sites (3). 
Subcellularly, the peripheral BZ binding sites occur 
most abundantly in the nuclear ($1) and mitochondrial frac­
tions, while central-type receptors are predominant in the 
synaptosomal and P2 fractions (22,56,90). The most strik­
ing species difference is that in the rat %-PK binding is 
highly enriched in the nuclear fraction, whilst this nucle­
ar enrichment is not seen in the cat or human (32). It has 
been suggested that the peripheral^type BZ recognition sites 
are located in the outer membrane of mitochondria (4,112). 
3. DEVELOPMENT OP THE PERIPHERAL-TYPE BZ BINDING SITES. 
The ontogenetic development of the peripheral BZ bind­
ing sites resembles that of the central receptors: both 
types of BZ receptors can be detected already on the 16th -
17th day of conception (3,21,77). Phylogenetically, the pe­
ripheral BZ binding sites appear later than the central BZ 
receptors; they are found in mammals only, while the latter 
are also detectable in fish, reptiles and birds (20,71). 
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4. ENDOCRINE REGULATION OF PERIPHERAL-TYPE BZ BINDING SITES 
The endocrine functions seem to alter the characteris­
tics of the peripheral-type BZ binding sites: adrenalectomy 
causes a decrease in the number of these binding sites, in 
kidney this change can be reversed with ezogeneous aldoste­
rone (6). Hypophysectomy also tends to decrease the number 
of the BZ binding sites in adrenals and in testes, and this 
change is more marked than the decrease in the weight of 
these organs - in the kidneys, brain, heart and lungs the 
characteristics of the peripheral-type BZ binding sites re­
main unaltered after the hypophysectomy (2). Ro 5-4864 in­
hibits ß-endorphine secretion from AtT-20 (anterior pitui­
tary-derived tumor cell line) cells through the blocade of 
the voltage-dependent membrane Ca2+ channels (18). Pituita­
ry stalk transection has been shown to increase markedly 
%-Ro 5-4864 binding in this organ (23). The deprivation of 
neural stimulation to the pineal gland by constantly keep­
ing the animal in illuminated conditions causes a selective 
diminishment of the peripheral BZ binding sites, while the 
central-type receptors in the pineal gland are not altered 
(108). In diabetes insipidus, the number of the peripheral 
BZ binding sites increased in the kidneys of Brattleboro rats 
(30). Exogeneous hormone also affect the peripheral BZ bin­
ding sites: thyroxine alters their density (38) and estra­
diol reduces their number in testis and increases it in the 
kidneys (40). 
5. PERIPHERAL-TYPE BZ BINDING SITES AND CALCIUM CHANNELS 
At micromolar concentrations the calcium antagonists 
nifedipine and nitrendipine competitively displace Ro5-4864 
from the peripheral BZ binding sites in brain, kidneys and 
heart. These drugs do not affect the binding of flunitraze-
pam to the central-type BZ receptors (24,87). This affinity 
for the peripheral BZ binding sites is not common for all 
calcium antagonists: diltiazepam and verapamil lack the a-
bility to displace the peripheral-type BZ receptor ligands 
(87). Nitrendipine inhibits potassium-induced cellular up­
take of calcium in the hypophysis of rats, and Ro 5-4864 at 
micromolar concentrations causes a similar effect, which 
2* 
11 
can be counteracting with PK 11195 (12). In the rabbit aor­
ta PK 11195 in a micromolar range of concentration behaves 
as an antagonist of voltage-operated calcium channels, but 
it does not interact with receptor-operated channels (62). 
In glia-oelle, BZe displace nitrendipine from its bind­
ing sites, exhibiting the same rank order of potency as in 
displacing diazepam from glia-oells. The BZ binding sites in 
the glia-cells are of the peripheral type (16). BZs in mic­
romolar concentrations also inhibit Ca2+ conductance in neu­
rons (49). Reoently it was demonstrated that(%-Ro 5-4864 
binds specifically«and eaturably to an apparently homogene -
ous, univalent type of binding site on the calmodulin mole­
cule (Kp 644 — 121 nM). Such binding of %-Ro 5-4864 was 
protein-, pH- and temperature-dependent and demonstrated 
pharmacological selectivity (68). 
All these flmdlttga suggest that the peripheral BZ bind­
ing sites might be^lieked with calcium channels (63) and o-
ther calcium mediated processes (68). However, it has been 
shown (47) that Ro 5-4864 at concentrations under 3 >un does 
not alter the calcium influx in the ventricles of heart dur­
ing depolarization. At higher concentrations, Ro 5-4864 de­
creased the ion-influx while causing negative inotropic ef­
fect on the papillary muscle. As the concentration needed to 
influence the movements of calcium is so high, the connec­
tion between the peripheral BZ binding sites in heart and in 
calcium channels does not seem entirely convincing. 
6. LIGANDS FOR PERIPHERAL-TYPE BZ BINDING SITES 
Several compounds with BZ structure show high affinity 
tKi values at nanomolar level) for the peripheral BZ bind­
ing sites, while pharmacologically active non-BZs usually 
lack this affinity, e,g. acetylcholine, atropine, carbacho -
line, adrenaline, phentolamine, propranolol and serotonin 
(98,99,103). On the other hand, in addition to nifedipine 
and nitrendipine, some vasodilators, such as cyclandelate or 
prazosin exhibit a moderate affinity (Ki against flunitraze-
pam in heart 7.1 and 30 >Ui, respectively) (87). Dipyridamole 
- a drug with vasodilating and anti-aggregatory properties , 
exhibits affinity with Ki value being 0.1 цМ (28). Also some 
antii-inflammatory analgesics possess affinity for peripheral 
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BZ binding aitee: proquazone has a rather high affinity, Ki 
0.14 pM, and also azapropazoae, diflunisal, fenoprofen, me-
fenamic acid, sulindac and tolfenamic acid show affinity Ki 
values ranging from 5-25 ДЫ (87). It haa been demonstrated 
that several anion transport inhibitors, like 9-anthroic a-
cid, furosemide, bumetanide, hydrochlorothiazide and SITS 
inhibit ^H-Ro 5-4864 binding to renal meabramee with Ki т»1-
ues from 30 te 130 pM whirh were consistent with their ac­
tione as anion transport inhibitors (5). The effects of 
long-term drug treatment have been less thoroughly investi­
gated. In schizophrenics medicated with antipsychotic drugs, 
a 30 % decrease in the number of peripheral BZ binding ait ее 
in platelets has been demonstrated (41). An increased num­
ber of renal peripheral BZ binding sites and diuresis was 
observed after five days administration of hydrochlorothia­
zide or Ro 5-4864 (5). 
7. PERIPHERAL EFFECTS OF Tffit PERIJHBRAL-TYPE 
BZ BIHDIHG SITE LIGANDS. 
One of the major reasons for considering the peripher­
al BZ binding sites as pharmacologically meaningless accep­
tor sites has been the relative absence of the BZs effects 
on the peripheral organs with high affinity for these re­
ceptors. One such example is diazepam. In therapeutic use, 
BZs produce their central effects at less than mg/kg dosage 
level, and hardly ever can any other effects be as important 
as those on the CMS. However, diazepam has been shown to ef­
fect the cardiovaacular system by increasing the coronary 
flow and by decreasing blood pressure and heart rate (27). 
Ro 5-4864 has negative inotropic action and it can specifi­
cally counteract with PK 11195 which also is a potent li-
gand for the peripheral BZ binding aites (64). These two li­
gands show opposite properties also in their effects on be­
haviour (65). 
Some reports have demonstrated changes in the charac -
teristics of the peripheral BZ binding aites in kidneys cor­
relating with hypertension (78,98,101), while in some stu­
dies the changes have not been observed. In a majority of 
cases, the affintiy of antihypertensive compounds for the 
binding sites mentioned, however, is very 1о«Г(87), vhich 
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suggests that the peripheral-type BZ binding sites hardly 
represent the pharmacological site of action of these drugs, 
although they may be the mediators of the regulatory proces­
ses concerned with blood pressure. Recently, the data indi­
cating that the peripheral BZ binding sites may have an ac­
tive role in the regulation of aldosterone secretion ha.ve 
been presented (92). 
BZs also exert a variety of slowly appearing effects on 
cultured cells. These compounds can induce cell differentia­
tion in the Friend erythroleukemia cells and block mitogen-
esis in the 3T3 cells (26). Melanoma cells possees the peri-
pheral-type BZ binding sites, and the melanogenesis in these 
cells can be enhanced with Ro 5-4864 (58). In pinealocytes , 
BZs increase the production of melatonin (59). BZs also in­
hibit the proliferation of cultured thymoma cells; these 
cells have also the peripheral BZ binding sites (102). Ro 
5-4864 stimulates the phospholipid methylation in the 06 as­
trocytoma cells (97). BZs appear to induce the Chemotaxis of 
human monocytes (82) and stimulate humoral immune response 
(115). Peripheral BZs have been reported to enhance the res­
piratory burst of macrofage-like P388D1 cells stimulated by 
arachidonic acid in a PK 11195 reversible manner (114). As 
the (^production is an important biochemical indicator of the 
defensive activity of macrofages against infection and ma­
lignant cells, the potential immunopharmacological useful­
ness of peripheral ligands remains to be elucidated. 
Dipyridamole, a non-BZ with high affinity for peripher­
al BZ receptors, has been used as an anti-melanoma agent 
with some success (79); dipyridamole also enhances the cyto­
toxic action of metotrexate (51). These findings may indi­
cate a pharmacological effect possibly related to interaction 
with peripheral BZ binding sites. At least in some cases, 
however, the potency in effect does not correlate with the 
affinity for the peripheral BZ binding sites (e.g. inhibi­
tion of neurite outgrowth in PC12 cell cultures (69)). 
/ 
8. CENTRAL EFFECTS OF THE PERIPHERAL-TYPE 
BZ BINDING SITE LIGANDS. 
Attempts to modify the benzodiazepine structure in or­
der to develop jiew compounds with more selective spectrum of 
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activity led to the synthesis of Ro 5-4864, no* recognized 
as a specific ligand for the peripheral BZ binding sites. In 
preliminary studies, this compound was shown to be effective 
against the electroshock-induced convulsions, to cause tran-
quilization, drowsiness and occasional ataxia being only 
slightly less effective than chlordiazepojti.de (116). However 
later it was demonstrated that Ro 5-4864 exhibits convulsive 
and anxiogenic actions in animal tests (73) that cannot be 
antagonized with the central-type BZ receptor antagonist Ro 
15-1788 (37). Moreover, the convulsive effect of Ro 5-4864, 
can be counteracted with PK 11195, which also is a ligand 
for the peripheral BZ binding sites (10# 35). On the other 
hand, Ro 5-4864 in a EK 11195 reversible manner blocked the 
anticonvulsant action of carbamazepine but not that of dia­
zepam on amygdala-kindled seizures (105). According to neu­
rochemical and pharmacological studies, it has been proposed 
that carbamazepine may exert some of its anticonvulsant ef­
fects by acting as a partial agonist at adenosine receptors 
(94). Recently it has been suggested that Ro 5-4864 has 
both antagonistic and potentiative interactions with adeno­
sine on the eerebral cortical neurons (74). This effect of 
Ro 5-4864 may partly explain the described interactions with 
carbamazepine. The Ro 5-4864 induced convulsions were blocked 
by diazepam and pentobarbital, but they were not blocked by 
the central BZ antagonist Ro 15-1788 (76). The activation of 
GABA receptors by amino-oxyacetic acid, the GABA-T inhibitor 
or GABA agonist, muscimol, protected, while the subconvul-
sive doses of bicuculline, a direct GABA receptor antagonist 
enhanced the convulsant action of Ro 5-4864 (76,106).The ex­
amination of a series of compounds that are structurally re­
lated to Ro 5-4864 revealed a good correlation between their 
potencies as convuleants and their -capacities to inhibit the 
•'^S-TBPS binding (107). These results support the proposal 
that a significant aspect of convulsant actions of Ro 5-4864 
is of central origin, and most likely the site of. action ap­
pears to be the Picrotoxin site of GABA-BZ receptor complex. 
However, it is important to take into consideration that the 
described neuropharmacological effects of the peripheral BZ 
binding site ligands have been obtained in rodents, and in 
the light of large differences between the regional and sub­
cellular distribution of peripheral BZ binding sites in rat 
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and in human (32) their relevance to human neuronal function 
does not become obvious. 
9. REGULATION OP PERIPHERAL-TYPE BZ BINDING SITES 
BY GABA AND STRESS. 
The majority of the central-type BZ binding sites in 
the CNS are linked to the GABA-reoeptor and chloride ion 
channel (44,46). The connection between the peripheral- type 
BZ binding sites and GABA receptors is not so clear yet. In 
vitro, GABA does not alter the binding affinity or the den­
sity of the peripheral BZ binding sites, and neither does 
the chloride ion (56,90). Moreover, there are no %-muscimol 
binding sites, no GABA-ergiс regulation, no barbiturate re­
gulation nor the ^S-TBPS binding present in the purified pe­
ripheral BZ recognition sites (57). Nevertheless, the appa­
rent molecular weight of solubilized peripheral- and central 
BZ receptors is quite similar: 215,000 and 260,000-270,000 , 
respectively (13,52). In contrast to these data, in vivo 
GABAA and GABAg agonists have been shown to alter both cent­
ral and peripheral BZ binding sites (84). Acute treatment 
of rats with muscimol and (-)baclofen resulted in a marked 
increase in the affinity of BZ recognition sites not only 
in cerebral cortex but also in kidneys. In addition to that 
the (-)baclofen treatment also lowered the number of BZ bdncfc-
ing sites in both structures studied (85). Several lines of 
evidence denionstrate that central BZ and GABA receptors are 
affected by stress (17,60). However, little is known about 
how stress can influence the peripheral-type BZ binding 
sites. A comparative study of naive (stressed) and handling-
habituated (unstressed) rats showed that also the number of 
both central and peripheral BZ binding sites was higher in 
naive rats (83). After forced swimming stress a significant 
increase in the density and a certain decrease in the affi-
nity of the H-flunitrazepam binding sites in the rat cereb­
ral cortex and kidneys were observed (86). Thus, the central 
and peripheral-type BZ binding sites seem to be regulated a-
naioRously by at least two stress models.Considering the a-
bove-meutioncd results, it was of great interest to study 
the action of stress on the peripheral-type BZ binding sites 
in blood platelets. According to our recent data (Table 1) 
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Table 1 
The effect of acute swimming stress (at 20 - 1°C) 
on peripheral-type BZ binding sites on intact 
blood platelets in rat. 
•%-Ro 5-4864 binding was carried out by incubation 
of the ligand at concentrations ranging from 0.75-
48 nM with ul of washed platelet preparation in a 
modified Hanks solution (pH 7.4) for 30 min at +4°C. 
Each value is the mean ± SEM of four separate ex­
periments, each carried out using pooled blood from 
8 rats. 
%-Ro 5-4864 binding 
Experimental -
group ВШ1 % KD (nM) % 
(pmol/ 10® cells) 
Control 6.8 ± 1.2 100 6.8 - 1.6 100 
Stress 4.1 - 0.7* 60 11.3 - 2.7 166 
i - P < 0.05 as compared with control rats 
swimming stress also enhanced the number and had a tendency 
to decrease the affinity of ^H-Ro 5-4864 binding sites on 
the intact blood platelets of rats. In contrast to this, in 
man, the binding capacity of peripheral-type BZ binding 
sites on the platelets of anxious patients has shown a cer­
tain reduction in comparison with normal controls (109)• A 
surprising similarity between the in vivo regulation of the 
central and peripheral BZ binding sites by GABA agonists and 
stress is difficult to explain. Recently, a new neuropep­
tide called DBI (diazepam binding inhibitor) that possesses 
a unique genetic code, which is located in neurons and can 
be released by depolarization, has been isolated (43, 45). 
The DBI mRNA is expressed not only in neurons but also in 
glial cells, in liver, kidney and-heart and its concentra­
tion has some features that are related to emotional state 
3 
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(45). Similar regulation of central- and peripheral-type 
binding sites by GABA agoniata and stress seems to support 
the idea that there must be at least one common endogenous 
ligand for both types of BZ receptors. The localization of 
relatively high concentrations of peripheral BZ recognition 
sites in pituitary and adrenals (31) may indicate the pos­
sibility that these binding sites could be involved in the 
neuroendocrinological regulation of emotional behavior. In­
directly this suggestion is supported by the data demon -
strating that the hyperthyroidism produced by chronical 
treatment increases the number of both central and periphe­
ral BZ receptors (39). There is no doubt that hyperthyroi­
dism can also change emotional behavior. 
In conclusion, although the mechanism by which GABA 
and stress can modulate peripheral BZ binding sites remains 
to be elucidated, a possibility to use peripheral BZ bind­
ing sites on blood cells (platelets for example) as the po­
tential markers of thd functional activity of central BZ re­
ceptors can be suggested. 
10. EKBOGfiHOUS LIGANDS AND THE PHYSIOLOGICAL ROLE 
OP THB PERIPHERAL-TYPE BZ BINDING SITES. 
Preeaing and thawing the membrane preparation from the 
adrenals of the rat increases the affinity of Ro 5-4864 
binding sites without affecting the number of these sites . 
A similar change can be brought about by detergent treat­
ment. It has been suggested that the increase in the affi­
nity may be due to the displacement of endogenous ligands 
from the peripheral BZ binding sites (39). Beaumont et al. 
(7) have detected compounds with Ro 5-4864 displacing acti­
vity from the blood' and urine of the man. In another study, 
acidified methanol extracts from stomach, kidney and lungs 
were found to inhibit only ^H-Ro 5-4864 binding to the pe­
ripheral BZ binding sites but not that of ^H-diazepam to 
central BZ receptors (55). BZ binding to kidneys can be aug­
mented by perfusion, possibly through washing out the endo­
genous ligand (90). In the guinea-pig .ileum, BZs inhibit the 
effect of cholecystokinin, but not that of neurotensin. 5-
HT or substance P (61). In a recent study, Verma et al. 
(112) have convincingly shown that porphyrins exhibit a ve­
18 
ry high affinity (Ki values less than 50 nM) for peripheral, 
or as they call them, mitochondrial BZ receptors. They sup­
port the hypothesis about a possible physiological role of 
this receptor as a regulator of the voltage-dependent anion-
channel already presented by Anholt (1). Porphyrins iould 
thus be the endogenous ligands for peripheral BZ receptors 
at least in the steroid forming tissues. The role of these 
receptors in nonendocrine tissues (e.g. in ventricles of 
heart, brain) is still obscure. However, recently the peri­
pheral BZ binding sites labeled by 11Q-PK 11195 have been 
characterized in the living heart of dog and human being by 
means of the positron emission tomography (25). Since it has 
recently been proposed that the peripheral BZ binding sites 
could be coupled to the calcium channel in heart (63). po­
sitron emission tomography opens way to the investigation dT 
this receptor in clinical situations. In brain, the role of 
the peripheral-type BZ binding sites is even more obscure 
than in the oregans outside the CNS. Recently, it has been 
reported that the number of these binding sites increased as 
a result of neuronal damage, which makes them a sensitive in­
dicator of the diseases involving brain, e.g. Parkinson's 
or Huntigton's disease (9). Moreover, the presence of high 
concentration of peripheral BZ binding sites on glial tumors 
suggests that human primary central nervous system tumors 
could be imaged and diagnosed using the peripheral BZ li­
gands labeled with positron- or ^-emitting isotopes (96). 
11. RECEPTORS OR ACCEPTORS? 
In spite of the lack of overwhelming convincing eri-
dence, the peripheral-type BZ binding sites are often re­
ferred to as peripheral BZ receptors. Originally the peri­
pheral-type BZ binding sites were established using a radio­
ligand binding method. However, although a radioligand may 
bind to a site, this site may not be a neurotransmitter re­
ceptor or another receptor of interest. Until the binding 
of a radioligand can be shown to be associated with a phar­
macological or physiological event, the mere fac.t of the ex­
istence of an even saturable specific high affinity binding 
cannot be quated with a receptor (53,80). A true receptor 
involves signal sensing and transduction, i.e. the following 
3* 
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binding with the receptor allosteric modulation of signal 
detection (which happena after the binding of a ligand with 
the central-type BZ receptors) and/or the signal transduc­
tion causes postreceptor events (receptor-effector coupling, 
second and third messengers) that lead to the pharmacologi­
cal or physiological response. Thus, a receptor involves 3 
consequent processes, while an acceptor site is only a bind­
ing site without a following signal transduction and physio­
logical response, ffhen defining a binding site as a receptor 
it is important to satisfy a number of criteria (Table 2). 
Table 2 
Specificity criteria for defining a recep­
tor (modified by Laduron, 1984). 
1. Drug displacement (agonists and antagonists belonging to 
different chemical or pharmaceutical classes) 
2. Binding (drug affinity) in vitro can be shown to be asso­
ciated with a pharmacological or physiological event 
3. Regional distribution or tissue specificity 
4. Subcellular distribution 
5. Saturability (finite number of sites) 
6. High affinity 
7. Reversibility 
8. Stereospecificity 
The fact that many of the criteria for defining a binding 
site as a receptor (Table 2) are satisfied by are satisfied 
by peripheral-type BS binding sites, is intriguing. Never­
theless, mainly the lack of a definitive drug effect follow­
ing the attachment of drug molecules on these recognition 
sites does not enable to determine whether they are indeed 
functional receptors or merely acceptor sites. con­
clusion, in spite of the gained success, the role of the pe­
ripheral-type BZ binding sites in mediating drug effects or 
physiological processes remains still obscure. 
y.O 
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Abstract: 
Chronical habituation of rats to the handling 
procedures preceding sacrifice led to changes in 
binding characteristics of ^H-flunitrazepam, %-
GABA, %-muscimol, ̂ -spiperone and ^H-diprenor-
phine. Differences were also registered in the 
blood concentration of growth hormone and in the 
amount of conjugated diene in frontal cortex. In 
the model of elevated plus-maze the habituated 
rats showed diminished exploratory behaviour. The 
differences in the binding parameters of several 
receptors and in the behaviour of the rat provide 
evidence that the habituated animals shewed great­
er emotionality. 
Introduction 
The effects of various models of stress and anxiety оa 
the CHS neurotransmission have bean extensive у оtmiiей 
in animals, using biochemical and behavioural teciia.:qu<ts. 
There ia substantial literature which shows thst tüc envi­
ronmental novelty, in various forms, activates the pitaiva­
ry-adrenal axis of stress-respor.ee. Per example, siricly 
moving rats and their housing cages frcm one plavc to an­
other leads to a repid rise in che с ort i с с у t его no, prolactin 
and thyroid stimulating ho.rr.cne (6,8). Similarly, transport­
ing .-nice or rats to places different frox the housing cage 
leads to the release ''n: r.vyh L-.L tit, пог пчт.',-.;и • r.f an<i adra-
5 
nai corticosteroids, these responses being resistant to ha­
bituation (11). 
In a series of experiments it has been shown (1,2) tlat 
GABA receptors in different brain areas may vary with the 
state of animals before sacrifice. Namely, the rats habitu­
ated to the handling procedures preceding sacrifice pre­
sented a higher number of GABA receptors than naive animals. 
The lack of resistance of habituated animals during hand­
ling procedures and the in vitro binding studies led the 
authors to the conclusion that the handling-habituated rats 
could be termed as unstressed animals (1,2). 
However, on the other hand, chronic intermittent expo­
sure of rats to a variety of unpredictable stressors has 
been widely used (15,22,9) as an animal model of depression 
inducing a variety of behavioral, neuroendocrine and neuro­
chemical alterations. 
In addition, handling prior to experimentation was re­
ported (25) to diminish the behavioral and hormonal differ­
ences in response to the novel situation between normal 
rats and those with decreased emotional reactivity. Reduced 
emotional reactivity in adulthood is also one of the most 
obvious effects of handling infant rats during their pre-
weaning period (24). These contradictory data prompted us 
to further characterize the biochemical and behavioral pa­
rameters of naive and handling-habituated rats. 
Materials and Methods 
Male albino laboratory rats (Rappolovo farm, Leningrad) 
were divided into two groups, termed as naive and handling-
habituated animals. The handling-habituated rats were ha­
bituated twice daily for 10-12 days to the handling manoeu­
vres preceding sacrifice by decapitation. Naive animals 
were left in their home cages for that period. To determine 
the exploratory activity of naive and habituated rats, an 
elevated plus-maze was used as described recently (20).Dur­
ing a 4 min test session the latency period of the first 
open part entry, the number of sectors crossed in open arms, 
and total time spent in open arms were measured. 
For binding studies the animals were killed by decapi­
tation without any previous experiments. Dissected and ho­
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mogenized brain regions, ren and adrenal were washed twice 
in ice-cold Tris-HCl butter (pH 7.4) by oentrifugation and 
resuspension. Five additional washes of membranes with Tris-
HC1 buffer were carried out for the GABA^ receptor binding 
assays. 
The binding of %-flunitrazepam (81 Ci/mmol, Amersham ) 
was carried out in the presence of 0.25-32 nM of the labeled 
ligand and 10 yuM flunitrazepam. After 60 min incubation at 
4° С the reaction was stopped by rapid filtration over GF/B 
Whatman filters, followed by three washes of 5 ml each with 
ice-cold buffer. 
САВАд receptors were assayed in extensively washed mem­
branes using 2-60 nM 'H-muscimo1 (18 Ci/mmol, Aaersham) and 
4-80 nM -*H-GABA (52 Ci/mmol, Aaersham). The incubation was 
carried out at 4° for 15 min and nonspecific binding was de­
termined in the presence of 10 yuM muscimol and 100 yuM GABA 
respectively. The reactions were stopped by oentrifugation 
at 10 000 g for 5 min. 
The binding of 0.1-4 nM of %-spiperone (72 Ci/mmol, A-
mersham) was determined after 30 min incubation at 37° 0 in 
the presence and absence of 10 p)l haloperidol. Opiate re­
ceptors were labelled with 0.2-6 nM %-diprenorphine ( 34 
Ci/mmol, Amersham) using 5 yuM naloxone to determine nonspe­
cific binding. The reaction was carried out at 20°C for 45 
min and stopped by oentrifugation at 10 000 g for 5 min. 
The values for the number of binding sites (BmqT) and 
the apparent dissociation constant (Ky) were determined for 
each individual binding experiment from the Scatchard plots. 
Growth hormone was measured in the serum of the trunk 
blood of decapitated animals using a radioimmunoassay kit 
(CIS). The conjugated diene assay of rat cortex was carried 
out according to the heptane-izopropanol method at 233-234 
nm (26). 
Results and Discussion 
Binding studies with %-f luni trazepam revealed clear 
differences between naive and habituated animals. Prom var­
ious tissues studied, reduction in the density of %-fluni-
trazepam binding sites of the habituated rats reached sta­
tistical significance in cerebral cortex, ren and adrenal 
5* 
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(Table 1). There was no significant change in the affinity 
of benzodiazepine binding sites. The diminished number of 
central benzodiazepine receptors in habituated rats resemb­
les the decrease observed by other authors after acute (18) 
and chronic stress-situations (5). 
Table 1 
%-fluni trazepam binding parameters derived from 
various tissues of naive and habituated rats. 




•^H-f luni trazepam binding 
Bmax (fool/ffl6 protein) KD (nM) 

































1 PC 0.05 as compared to naive animals 
36 
Reduction in the number of the peripheral benzodiaze­
pine binding sitea of habituated rata (Table 1) say be re­
lated to the recent findings (7) of a decrease in the den­
sity of peripheral benzodiazepine binding sites in a strain 
selectively bred for a high degree of "fearfulnees". Thus, 
our results of -^H-fluuitraaepam binding demonstrate some 
neurochemical signs of anxiety in habituated rats, an ef­
fect observed simultaneously in the central and peripheral 
type benzodiazepine receptors. 
Table 2 
Binding parameters of brain GABA& receptors of 
naive and habituated rats. 
%-muscimol (^H-MUSC) and %-GABA were used to 
characterize ВАВАД-receptors. Bach value is the 
mean - SEM of 3-6 separate experiments. 
• Brain region Ligand ®max *D 
Group (fmol/mg protein)(nM) 
С E R E В В A L C O R T E X  
Naive 3H-MUSC 3160±180 25.3-1-7 
Habituated гбго^зо1 22,7*5.3 
Naive ^H-GABA 3650±280 220-24 
Habituated 2520±260x 180-15 
H I P P 0 С A M P U S  
Naive ^H-MUSC 1730*120 23.5-3.0 
Habituated 1250±110х •3.3-1.1 
с E R E B E L L  U M 
Naive ^H-MUSC 1860±14У !d. v-r . 
Habituated 1970-160 21. 3-.-' v 
1 P < 0.05 аэ compared to naive animals 
The data presented in Table 2 indicate that the number 
of ОАВАд receptors is lower in the cerebral cortex and hip­
pocampus of habituated animals, but not in the cerebellum. 
These results are in conflict with the results of Biggio 
(2) who registered a higher number of low-affinity GABA 
binding sites in cortical membranes of handling- habituated 
rats using slightly different experimental conditions. The 
discrepancies can be explained in at least two ways. First, 
it is well known (16) that the differences in the tissue 
preparation and buffers used for ^H-GABA binding assay can 
lead to different binding characteristics. Secondly, it has 
been recently suggested (10) that stress can affect the sen­
sitivity of the components of the GABA-benzodiazepine su-
permolecular complex to chloride ions. Thus, the results in 
Table 2 can reflect a change in the coupling between chlo­
ride ionophore and GABA receptor rather than a direct ef­
fect on the GABA receptor. 
With the intention to find the behavioral correlates 
to the changes in benzodiazepine and GABA binding sites, an 
elevated plus-maze model was used, reported to be a specif­
ic measure of anxiety in the rat (20). 
Table 3 
Exploratory activity of rats in an elevated 















Naive 12.2-2.1 13.6*1.4 123*13 0.4*0.2 
Habituated 18.8*2.8 8.5*0.8* 82*13* 2.1±0.5* 
x P 0.05 as compared to naive animals 
Table 3 shows that in our experiments the handling-ha­
bituated animals showed lower explorstory activity and hitl­
er defecation rate than naive rats. Diminished exploratory 
activity after various chronic stressors has been reported 
by several authors (9,22,5) and differences in open fieldde-
fecation have been interpreted as an indicator of emotiona­
lity (3). Therefore, it can be assumed that actually 
i8 
chronic exposure to the stressors in our experiments result­
ed in a decreased exploratory activity and defection, and, 
thus, the habituated rats behaved like "stressed" animals, 
e.g showed greater emotionality in the test model used. 
Peroxidation of unsaturated lipids has become an at­
tractive hypothesis for the explanation of various patholo­
gical conditions, including stress (4). Since lipid peroxi­
dation is related to oxygen metabolism in biological sys­
tems, it is assumed that lipid peroxidation can be set into 
motion whenever the conditions of the increased oxidative 
stress (increased production of free radicals and/or de­
creased antioxidant defences) occur in the cell (14). 
Table 4 
Values of conjugated diene and growth hormone 
of naive and habituated rats. Results are ex­
pressed as a mean - SEM for groups of 9 rats. 
Conjugated diene Growth hormone 
(unit/100 rag tissue) (ng/ml serum) 
Naive 114.5*16.3 0.84*0.12 
Habituated 130.0*22.8 1.13-0.18 
From several products of lipid peroxidation reactions, 
the amount of conjugated diene was determined in this study 
from the cerebral cortex of naive and habituated rats.( see 
Table 4), In the habituated rats the amount of conjugated 
diene was found to be higher than in the naive animals, al­
though the differences were not statistically significant . 
However, the increase of conjugated diene described here is 
in agreement with the hypothesis on the protective adapta -
tion in lipid metabolim during the initial stages of stress 
(14). Benzodiazepines, GABA and various stress situations sti­
mulate the growth hormone secretion in the man and in the 
rat (for review, see 23).In our studies the blood-level of 
growth hormone was higher in the handling-habituated rats 
(Table 4), thus indirectly indicating more stressful expe­
riences of habituated animals compared with naive ores. 
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The stress-induced increaee in the level of growth- hormone 
hae been reported using several stressors including elec­
tric shook (17) but these models are not comparable to the 
handling-habituation procedure used in this study. Moreover, 
the differences in the blood-level of the growth-hormone of 
the naive and habituated rats in our studies was not sta­
tistically significant and therefore, no conclusive deci­
sions should yet be drawn. 
In a further study an attempt was made to investigate 
the effects of handling on the receptors of catecholamines 
using %-spiperone as a labelled ligand and haloperidol to 
determine nonspecific binding. 
Table 5 
^H-spiperone (%-SPI) and -%-diprenorphine (%-DIP) 
binding parameters derived from brain tissue of 
naive and habituated rats. Bach value is the mean 
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Table 5 continued 
1 2 3 4 
Naive ^H-DIP 280*13 0.86*0.10 
Habituated 210*20x 1.27*0.11х 
x P < 0.05 as compared to naive animals 
Of the three brain regions studied (Table 5). statisti­
cally significant differences were registered only in the 
mesoliabic region (e.g., structures ventral to striatum). 
Namely, the number of ^H-apiperone binding sites was smaller 
in the mesolimbic region of the habituated rats. It is dif­
ficult to interpret these results because the ligand combi­
nation used for this binding assay labels not only dopamine 
receptors but also some subgroups of serotonin- and oc -ad-
renoreceptors. Moreover, the majority of the reports inves­
tigating the influence of stress on the brain catecholamines 
deal with the release and metabolism of these biogenic er 
mines. To our knowledge, there is only one previous report 
concerning the effect of the chronic low-level stress on the 
brain ^H-spiperone binding (21) and it was found that chron­
ic prenatal stress increased the ^H-spiperone binding in the 
cerebral cortex and hippocampus. In our studies, a statisti­
cally insignificant increase in the number of binding sites 
of ^H-spiperone in the cerebral cortex of the habituated 
rate was found (Table 5). Nevertheless, our binding data 
suggest that handling procedures can influence the ^{-spipe­
rone binding characteristics. Whether this influence ia 
caused by the changes in dopamine, serotonin or oc -adreno-
receptors, remains to be established. 
The role of the endogenous opiate system in stress haa 
been investigated frequently (for review, see 19). Several 
authors have also provided evidence that the persistent ac­
tivation of opiate receptors by the endogenous opioids re-' 
leased during restraint-stress leads to the receptor "down-
regulation" (12,13). In our studies, the reduction in the 
3 number of the 'H-diprenorphine binding sites of t-.it,- haiid-
lin,=;-habi tuated animals could be registered in all brain re-
gione Stadl«« (ТвЫ# 5) > reaching statistical significance 
in the oeretnrti eortex aed sesoliebic structures. A decrease 
in the apparent affinity for %-diprenorphine was also ob­
served in the seeoli*bic structures of the habituated rats, 
fo decide whether these effects were also secondary to the 
stress-induced release of endogeneous opioids or not, more 
complete studies are required. 
The present study provides the evidence that handling 
manoeuvres yield narked changes in the binding parameters of 
several receptors in the CHS and in peripheral organs and in 
the behavior of the ret. 
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CHANGES IN GABA AND BENZODIAZEPINE RECEPTORS APTER 
FOOT-SHOCK IN THE RAT: INFLUENCE OF DIAZEPAM 
R.-A. Kiivet, J. Harro, L. Rägo, and M. Pold 
Department of Pharmacology 
Abstract: 
JtiMi binding studies revealed that foot-shock 
decreases the number of %-flunitrasepam and %-mus-
cimol binding sites in frontal cortex and hippocam -
pus. A decrease was also registered in the peripher­
al ^H-flunitrazepam binding sites in ren and adre­
nals. This effect was of the same range both in the 
naive rats and in those chronically habituated to 
the handling procedures preceding sacrifice. The ef­
fect of foot-shock on binding parameters was not at­
tenuated by in vivo diazepam (2.5 mg/kg) administ -
ration. 
Introduction 
Stressful situations are known to produce numerous neu­
rochemical and hormonal changes. Since benzodiazepines (BD) 
can counteract several of the effects produced by stress (3, 
10), and the GABA-ergic system is reported to play a regula­
tory role in stress-induced hormone release (5,9), inves­
tigation of the possible involvement of the BD and GABA re­
ceptors in stress is of great importance. 
The information concerning the changes of the BD or GABA 
receptors following stress is rather contradictory, probably 
due to the great variability in the stress situations used. 
Stressful manipulations are reported both to increase (17) 
and decrease the number of the brain .BD receptors (12,14).It 
lias been shown (1) that the GABA receptors different 
brain areas may vary with the state of animals before sac-
th 
rifice: the rate habituated to the handling procedures pre­
ceding sacrifice presented a higher naaber of GABA recep­
tors than naive animals. On the basis of this evidence, na­
ive and handling-habituated rats were proposed (2) as a 
useful model to etady the effect of •trees on GABA recep­
tors. 
In the present study, we report that foot-shock de­
creases the number of %-flunitraeepam and ^E-muecimol bind­
ing sites in various tissues of both naive and habituated 
rats - an effect not attenuated by the in vivo diazepam ad­
ministration. 
Materials and Methods 
Male albino laboratory rats (Rappolovo farm, Lenin­
grad) were divided into two groups, termed as naive and 
handling-habituated animals. The handling-habituated rats 
were habituated twice daily for 10-12 days to the handling 
manoeuvres preceding sacrifice by decapitation. The naive 
animals were left in their home cages for that period. Im­
mediately before saerifice half of the rats from both 
groups were treated with a 3 min. intermittent foot-shock 
(60 Hz, 0.5 •*., 10 s on every 15 s). In a separate study , 
diacepam (2.5 mg/kg) or vehicle 60 min. prior to the foot-
shock was adninistered intraperitoneally to the naive and 
habituated animals. 
After decapitation cerebral cortex, hippocampus, ren 
and adrenal were rapidly diosected and homogenized in 30 
volumes of ice-cold Tris-HCl buffer (pH 7.4). For ^H-flu-
nitrazepam binding the homogenate was centrifuged twice at 
48 000 g for 20 min. and resuspended finally in the Tris-
HCl buffer containing 0.1-0.3 mg of protein per sample. 
Binding of ^H-flunitrezepam (81 Ci/mmol, Amersham Radio­
chemicals) was carried out in the presence of 0.25-32 nM of 
the labelled ligand and 10 pH flunitrazepam. The incubation, 
performed at 4° С was terminated 60 min . later by filtra -
tion under vacuum through GF/B Whatman filters, followed by 
3 washes of 5 ml each with ice-cold buffer. 
For %-muscimol binding, the tissues under study were 
washed 3 times in Tris-HCl buffer (48,000 g for 20 rain.), 
stored at -20° С for at least ?A hours qnd washed 4 addi-
tlonal times immediately before the binding assay. 'H-musci-
mol (18 Ci/mmol, Amersham Radiochemicals) binding was car­
ried out in the presence of £-60 nM of the labelled ligand 
and 10 yuM muscimol in a total incubation volume of 500 .ill 
'containing 0.3-0.4 mg of protein. After 15 min. of incubation 
'at 4° С the reaction was stopped by oentrifugation at 10,000 
g for 5 min. The characteristics of the binding data ( 
and Ky) were obtained with the help of the Scatchard analy­
sis. The significance of the differences between groups was 
calculated using the Student's t-test. 
Results and Discussion 
An intermittent foot-shock decreased the number of bind­
ing sites of ^H-flunitrasepam and ^H-muacimol in the mem­
branes of cerebral cortex and hippocampus of the naive rats 
(Table 1). In this experiment the binding of the two Uganda 
studied vary in the same direction without any changes in 
affinity. The alterations of the BD receptors were of the op­
posite direction to those observed in the convulsive states 
produced by electroshock (15)« but resembling the decrease 
in the number of BD receptors after forced swimming (14). 
In our studies, the foot-shock was able to attenuate al­
so the number of %-muscimol binding sites in naive rats (see 
Table 1), the effect that was not found in naive rata by 
others (2) when %-GABA was used to label the 0АВАд recep­
tors. The discrepancies in the binding studies using %-mus-
cimol or -*H-GABA as a ligand have been reported in various 
situations (8,13) and for explanation it has been suggested 
that -muscimol does not label all, but mainly the postjunc­
tional вАВАд receptors (4). On the other hand, the decreased 
number of the binding sites of %-muscimol after a foot-
shock in habituated rats (Table 2) is in good correlation 
with the results obtained with the help of %- GABA (2). 
The foot-shock-induced reduction in the density of the 
GABA and BD receptors in the cerebral cortex and hippocam­
pus of habituated animals (Table 2) corresponds to the de-
3 3 crease in the vH-muacimol. and vH-flunitrazepam binding sites 
that we observed in naive animals (Table 1). So, in our ex­
periments there wnre no clear differences between the naive 
and the habituated animals in the foot-shock-induced effects 
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Table 1 
Effect of foot-shock on the characteristics of %-flu­
ni tr&sepaa (%-PNZ) and. %-muscimol (^H-MtJSC) binding 
to washed, aembrenes of naive rata. 
Bach value is the mean - SEM of 3 separate experiments. 






































F < 0.05 as compared to naive animals 
Table 2 
Effect of foot-shock on the characteristics of ^H-flu-
nitrazepam (^H-FNZ) and ^H-muacimol (%-MUSC) binding 
to washed membranes of handling-habituated rats. 
Each value is the mean ± SEM of 3 separate experiments. 
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C E R E B R A L  С  0  R  T  К  X  
3H-t'NZ 1 380± 30 1.17±0.16 
1.02-0.09 





Table 2 continued 
1 2 3 





%-MZ 960± 70 1.16*0.10 
920± 50 1.28±0.08 
H60±130 20.7 ±2.9 
1020± 70 18.6 ±2.3 
Зн-мизс 
* P < 0.05 aa compared to habituated animals 
on central BD and GABA receptors. Thus, it can be suggested 
that handling procedure has no effect on the direction and 
size of the BD and GABA receptor alterations after foot -
shock. However, it is important to note that the handling 
procedure was able to decrease the basal density of both 
^H-flunitrazepam and ^H-nruscimol binding sites without sig­
nificant changes in the affinity. 
Recently we observed (16) similar modulation of cent­
ral and peripheral BD receptors by different GABA agonists 
and these findings led us to the investigation of the pos­
sible changes in the peripheral BD receptor binding charac­
teristics after foot-shock. We found that the number of %-
flunitrazepam binding sites was decreased after the foot-
shock in the washed membranes of ren (Fig. 1) and adrenal 
(Pig. 2) in both naive and habituated rats. The changes of 
the peripheral BD receptors were parallel to those observed 
in the brain. The attenuating effect of the handling proce­
dure on the number of peripheral binding sites of ^H-fluni-
trazepam was registered also in the peripheral tissues 
studied. 
These observations suggest that the peripheral BD bind­
ing sites are modulated similarly to the central BD recep­
tors: the density of the peripheral BD binding sites is de­
creased, following a stressful situation. Recently, it has 
been reported that (6) the exposure of rats to an inescap­
able tailshoeк produced a reduction in the density of the 
peripheral BD binding sites in heart and kidney but not in 
the other tissues surveyed (e.g., CNS and adrenal gland ) . 








1000 2000 3000 4000 BOUND 
Fig.1. Scatchard analysis of a representative experiment 
of ^H-flunitrazepam binding to washed membranes 
of rat ren after foot-shock. 
Bmax 
(fmol/mg protein) 
3860 + 280 
2900 + 220 * 
3310 + 140 
HS - habituated + shock 2730 + 160 ** 
* P < 0.05 as compared to naive animals 
H P < 0.05 as compared to habituated animals 
N - naive 
NS - naive + shock 
H - habituated 
D 
(nM) 
12.2 + 1.3 
10.8 + 1.0 
13.6 + 1.6 








5000 10000 15000 20000 BOUND 
Fig.2. Scatchard analysis of a representative experiment 
of ̂ H-flunitrazepam binding to washed membranes 
of rat adrenal after foot-shock. 
N - naive 
NS - naive + shock 
H - habituated 




15,100 + 1,100* 
15,500 + 900 * 
12,200 + 800 ** 
ttD 
(nM) 
29,3 + 4.5 
25.6 + 4.3 
23.7 + 2.8 
24.8 + 4.5 
P < 0.05 as compared to naive animals 
* P < 0.05 as compared to habituated animals 
plained with different Uganda and stress models used and 
the differences in the tissue preparation far binding stud­
ies. Nevertheless, a systematic investigation of the hormon­
al and neural regulation of peripheral organs may shed some 
light on the etiology of the stress-induced reduction in the 
density of peripheral BD binding sites in various tissues. 
The next series of experiments was designed to study the 
effect of diazepam on the foot-shock-induced changes of BD 
and GABA receptors. 
Table 3 
Influence of acute treatment-with diazepam (2.5 mg/kg) 
and foot-ehock on the binding of ^H-flunitrazepam to 
the washed membranes of rat cerebral cortex. 
Bach value is the mean - SEM of 3 separate experiments. 
Animal group Treatment Bmax 
(fmol/mg protein) (nM) 
H A I V E A N I И A L S 
Control vehicle 1560 ± 120 1.15 + 0.12 
Control diazepam 14Ю - 120 1.23 + 0.09 
Shock vehicle 1120 - 90* 1.06 
+ 
0.15 
Shock diazepam 1180 - 70* 1.11 
+ 
0.12 
H А В I T Ü A T в D A N I  A L S 
Control vehicle 1360 ± 300 1.20 + 0.15 
Control diazepam 1180 - 80 1.06 + 0.18 
Shock vehicle 1020 - 60* 1.23 
+ 0.10 
Shock diazepam 950 - 100* 1.11 j; 0.12 
* P < 0.05 as compared to control + vehicle group 
Table 3 shows an example from these studies. Diazepam has 
been shown to attenuate the biological consequences of expo­
sure to a stressor (2,7,10,14). Surprisingly, in our studies 
diazepam (2.5 mg/kg) was unable to modulate the stress-in­
duced changes in either ^H-flunitrazepam or H-muacimol 
binding characteristics in all tissues studied and in both 
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naive and habituated animals. On the other band, using other 
models it bae been shows that diazepam potentiated some ef­
fects of a stressor (11) or prevented the stress-induced bio­
chemical changes only iit relatively high doses, e.g. 10 tag/ 
kg (7). Therefore, в tao «mall doae of diazepam used could 
be the most probable explanation for the lack of the effect 
of diazepam in our studies. 
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THE FUNCTIONAL ROLE OP DOPAMINE 
D1 RECEPTORS IN THE CNS 
K.Z. Õereaka and A.M. žharkovsky 
Department of Pharmacology and 
Laboratory of Hormonal Regulation, 
Tartu University 
Abstract: 
In experiments with rat brain membranes the 
binding of selective D1 receptor agonist SKP 38393 
h a s  b e e n  s t u d i e d .  I t  h a s  b e e n  f o u n d  t h a t  f S K F  
38393 binding is largely dependent on the buffer 
used and on incubation conditions. The maximal ratio 
specific to nonspecific binding was achieved by us­
ing phosphate buffer and incubation at 0° C. Since 
glass-fibre filters were found to adsorb radiolig­
and in a great extent, the bound radioligand was sep­
arated by microcentrifugation. Under these condi­
tions, hi SKF 38393 binds in striatum to the single 
receptor population with BmaT = 384-43 fmol/mg pro­
tein and Kq = 5.8-1.0 nM. The regional distribution 
of D1 sites well corresponded to the distribution of 
D2 sites labeled by ^H spiperone in the rat fore -
brain. 
Several neuroleptic drugs and dopamine receptor 
agonist varied in their binding affinities for both 
D1 and D2 receptors. Comparing the ability of neuro­
leptics to induce catalepsy and their affinity for 
01 sites, it is proposed that the blockade of D1 re­
ceptors might among other factors account for the 
cataleptic properties of these drugs. 
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Introduction 
Op to the present, at least two different types of do­
pamine receptors have been described (9), which can be i-
dentified on the basis of their linkage to adenylate cycla­
se. Thus, the dopamine D1 receptor is associated with the 
dopamine sensitive adenylate cyclase, whereas the recep­
tor is independent of it or is even involved into the in­
hibitory control of adenylate cyclase (17). 
There is enough evidence to suggest that the majority 
of the behavioral and biochemical effects of dopamine ago­
nists and antagonists are mediated via the U2 receptors, 
whereas the role of the D1 receptors remains unknown. 
The recent introduction of a novel selective recep­
tor agonist SKP 38393 and antagonist SCH-23390 has pro­
vided an invaluable tool for studying the functional role 
of these receptors (6,13,14). 
The behavioral and neuroohamloel effects of SKP 38393 
in many aspects differed from.the other dopamine receptor a-
gonists. Thus, SKP 38393 did not Induce stereotyty and did 
not influence dopamine release (11,16). However, similarly 
to the D2 receptor agonists, SKP 38393 induced contralater­
al rotations in the 6-hydroxydopamiae lesioned rats (1).Re­
cently, the tritium labeled SKP 38393 with high specific ac­
tivity was introduced that opened a possibility to study di­
rectly the interaction of various dopamine receptor ago­
nists with the D.j receptor thjfs enabling to elucidate the 
precise role of these receptors in the dopamine-mediated be­
havior. In the present study, an attempt has been made to 
study the potentials of several drugs of the binding of the 
D1 and D2 receptors labeled by Н/ SKP 38393 and /%/spi­
perone and to compare with their behavioral effects in rata 
Material and Methods 
Animals: In our experiments male rats and male mice 
170-250 g and 20-25 g, respectively, weie used. 
DriiKa: The following drugs were dissolved in saline: 
;;кP (У,3»4,5-tetrahyd.ro~1 -phenyl-1H-3-benzazepine-7,8 
dioi, hydrochloride) obtained as a gift from the Smith, Kii­
ru: and Fronch iAboratorieu (I'Uiladelphia, USA); Ly 171 555 
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(trans-(-)- 4 afi-4, 4a,5,6,7,8,8a,9-octahydro-5-propyl~; 1H 
(oF 2H)-pyrozo-(3.4-g)qulnoline, monohydrochloride) ae a 
gift from the Lilly Research Laboratories (Iadianopolie,USA)$ 
Chlorpromazine (USSR); Carbidine (USSR); leaailane ( Insti­
tute of Organic Chemistry, Latvian Academy of Soi., Riga); 
Raclopride (S)-(-)-3,5-dichloro-S-(1-etbyl-2-pyrrolidinyl ) 
methyl-6-methoxyealicylaeide) as a gift from Astra AB (Swe­
den) ; Remoxipride (S-(-)-3-bromo-2,6-dirothoxy-N-/(1-ethyl-
2-pyrrolidinyl)methyl/-benzamide) as a gift from Astra AB 
(Sweden); SCH 23390 I(R)-(+)-8-chloro-2,3,4,5-tetrahydro- 3 
methyl-5-phenyl-1H-3-bensasepine as a gift from Sobering 
Corporation (Kenilwortb, OSA); Clozapine ( Sandoz, Basle, 
Switzerland); Azaperone (Janssen Barmaceutica, Beerse,Bel­
gium); (+) and (-) Sulpiy*p CBarizaa, Italy); Butaclamol 
(Abott Labs., USA); На1одог16ф1 (Janssen Pannaceutica.Beer-
se, Belgium) were dissolved in hydroohloric acid before di­
lution with water. Apomorphine HCl (USSR) was dissolved in 
saline containing 0.05 % ascorbic acid. 
Receptor binding; »In vitro* ^H-spiperone binding was 
performed according to the method of Müller and Seeman (12). 
The rats' were sacrificed by the cervical dislocation. The 
brains were rapidly removed, the striata were dissected out 
on the ice-cold plate and weighed. Freeh tissues were homo­
genised with a glass-teflon homogenizer (1000 RPH, 9 pas­
sages) in 10 vol of 50 mM TRIS HCl buffer (pH - 7.4), the 
hoeogenate was centrlfuged twice at 40,000 g for 20 min with 
intermediate resuspension in a fresh buffer and finally 
homogenised in 750 vol of the TRIS HCl buffer containing 120 
mM HCl, 5 mli KCl, 1 mM Mg Cl^ and 2 laK Teat tub?s Re­
ceived 0.8 ml of membrane suspension (0.1-0.15 of prote­
in), 100 ul of buffer or 1 uM of haloperidol and 100 ul of 
%1-spiperone (77 Ci/mmsl "Amerehaa", England), final о otter. 
0.25 nM. The samples were incubated at 37° С for 30 roie add 
rapidly .filtered through QP/B (Whatmnu) filters under vncu-
urn. Following three 5 ml washes with iicubation buff«1 
filters were pLace-l . n scintillation rials, 10 ml ot eoiU-
iillation cocktail vieri1 added. The *anipies *ere oount<A 
'•<Ith a Beekmat: LS-бнОО couatcr with the 45-47 * cffloteoey. 
Specific bindiiv: of ^/H/-spiperone *аз de?jriod as tilSt 
piacoab Le by 1 uW haloperidol. 
") г. vitro* 3S3')'i Binding wae rs -/o .-sed 
S 
ing to the method of Gredal and Nielsen (4) in our modifica­
tion. The fresh striatal tissue was homogenized in 10 vol of 
ice-cold 50 mM of potassium phosphate buffer (pH =7.4) us­
ing a glasa-teflon homogenizes (1000 HEM, 9 passages). The 
homogenate was oentrifuged twice at 30000 g for 10 min with 
an intermediate rehomogenization in fresh cold buffer be­
tween centrifugations. The final pellet was resuspended in 
potassium phosphate buffer in a 500 V containing 40 mM of 
HaCl. Teat tubes received 0.8 ml of membrane suspension (0.1 
mg of protein), 100 ml of buffer or 10 uM SCH 23390 and 100 
ml of /%/SKF 38393) 50 Ci/mmol "Ameraham™, England). The 
samples were incubated at 0° С for 60 mitt and were oentri­
fuged in a Microfuge 12 (Beckman) 12,000 RPM for 4 min. The 
buffer solution was aspirated and the tube was washed twice 
with the same buffer. The samples were counted with a Beck-
man 15-6800. The specific binding of %-SKF 38393 was de­
fined as thatdisplaoeable by 10 uM SCH 23390. Proteins were 
determined by the method of Lowry (10). 
Behavioral Studies 
Catalepsy was assessed in rats according to the method 
of Honma, Fukushima (5). Briefly, at various times after 
drug treatment the animals were placed by their forepaws on 
the horizontal bar positioned 8 cm above the floor and the 
time in sec (max 300 sec) during which animals remained in 
such a position was recorded. 
For the stereotyped behavior measurement the rats were 
placed into individual square Plexiglas boxes (15x15x15 cm). 
The intensity of stereotyped behavior was assessed according 
to the system described by Costall and Naylor (3). For the 
assessment of the vawnings. the rats were placed into in­
dividual boxes. The number of episodes of yawninga was re­
corded during a 60 min test usirvs a hand-held counter. 
3 tat.istica 
The results were expressed as mean - SEM. IC^q werecel-
culated from log-dose response curves. Statistical compari­
sons of behavioral data were calculated using the Dunnet t-
test. Statistical comparisons of binding data were calcu­
lated using Student's t-test. 
S8 
Results 
Binding characteristics of /%/-SKP 38393. The binding 
of /%/ SKP 38393 showed a great dependency between the com­
position of incubation buffers and temperature. The highest 
specific binding was obtained if the incubation was per -
formed at 37°C in the THIS HCl buffer containing 120 mM of 
NaCl, 5 mM KCl, 1 mM MgClg and 2 mM CaCl2 or in the potas­
sium phosphate buffer containing 40 mM of HaCl at 0°C ( see 
Table 1). However, the specific binding of У^Н/ SKP 38393 
In the TRIS HCl buffer was not saturable and increased with 
increasing of the concentrations of ligand (data not shown). 
Furthermore, it has been found that a considerable amount 
of radioactivity was retained on the tubes and GP/B filters 
if the binding was performed in the TRIS HCl buffer ( Table 
2). When the binding was performed in the potassium phos­
phate buffer at 0°в in microfuge tubes, a minimal amount of 
radioactivity was recovered from the surface of the tubes. 
Therefore, these conditions'were used in the further exper­
iments. The binding of /%/ SKP 38393 was saturable 16 con­
centrations ranging from 0.25 to 16 nM (Pig. 1) and reached 
4 the equilibrium within 30-60 min at 0°C. As revealed by the 
Seatchard analysis, in the striatal tissue '/"*H/ SKP 38393 
binds with a single population of sites with KD * 5-8 - 1.0 
nM and maximal capacity (Втдт) of 384 - 43 fmol/mg of pro­
tein, while the bound ligand was separated by centrifuga-
tion and Kjj - 5.7 - 1.0 nM and ВтиТ » 591 - 236 fmol /mg 
of protein if the binding was stopped by the filtration 
through the GP/B filters (Pig. 2). 
Regional distribution of /%/ SKP 38393 and /%/ spi­
perone binding. As revealed by the binding studies, the re­
gional distribution of the D1 sites closely correlated (r * 
0.9) P 0.05 to the distribution of the D2 sites (Table 
3). 
The effect of various DA receptor agonists and antago­
nists on the /%/ SKP 38393 and /%/ spiperone binding and 
on the behavior of rata. There were considerable differen­
ces between the DA receptor agonists in the binding affini­
ties for the D1 receptors labelled by the /"W SKP 38393 
and D2 receptors labelled by /%/ spiperone (Table 4). The 
order of potencies for /\/ SKP 38393 binding were SKP 





Binding of /%/ SKP 38393 (2 nM) to striatal 
membranes in TRIS-HCl and potassium phosphate 
buffers. Monspecific binding was determined 
in the presence of 10™^ м of SCH 233SO 
Assay 
conditions 
/\/ SKF 38393 bound, CPM 
Total Nonspecific Specific % of 
total 
Phosphate buffer 
(filters) 37°C 3631 3618 13 0.4 
TRIS-HCl buffer 
(filters) 37°C 10878 3568 7310 67 
(tubes) 37°C 7183 1752 5431 76 
Phosphate buffer 
(filters) 0°C 1981 987 994 50 
(tubes) 0°C 1934 916 1018 53 
TRIS-HCl buffer 
(tubes) 0°C 3335 3037 298 9 
that, the order of potencies for /%/ spiperone binding 
was as follows: apomorphlne л- dopamine > Ly 171555>5036393. 
However, the ratio D1/D2 was the highest for Ly 171555 and 
the lowest for SKP 38393 suggesting high specificity of Ly 
171555 and SKP 38393 for D2 and D1 receptors, respectively 
(Table 4). The affinities of Ly 171555 and apomorphine for 
/^H/ SKP 38393 or /%/ spiperone binding did not correspond 
to their ability to induce yawning behavior (Table 3). The 
effect of neuroleptics on the /^НУ SKP 38393 and /^Н/ spipe­
rone binding is presented in Table 5. The most potent inhi -
bitory activity for /-^H/ SKP 38393 binding possessed SCH 
23390 (+) butaclaaol ^ haloperidol, the least potent -sul­
piride, raclopride, carbidine. (+) Butaofamol and haloper!-
dol were also the potent inhibitors of /%/ spiperone bind­
ing, whereas SCH 23390 was not. It should, however, be point­
ed out that the potency of a neuroleptic to coopete for the 
B1 sites corresponded well to their ability to Induce cata-
60 
Tabl« 2 
Binding of /^Н/ SKF 3R393 (4 nM) to filterо 
and micro fuge tubes in various buffers and 
conditions of incubation 
/^/SKJ? 
Assay 
38393 bound, (СИ/ filter, 
CPM/tube) 
condi tions 
Total + 10 u!,5 ЗСР 23390 
Pi]ter (OP/B Whatman) 2898 2057 
TRIS-HCl bvffer 37 °C 2898 2057 
Phosphate buffer 37°G 556 484 
Phosphate buffer 6°C 407 316 
Microfuge tube 
TRIS-HCl buffer 37°C 470 221 
TRIS-HCl buffer 0°C 1444 1377 
Phosphate buffer 0°C 126 89 
lepsy (Table ). An exception was clcsapine which potently 





Binding of /%/ SKP 38393 ( 4 nM) and 
/^Н/ spiperone (0.25 nM) in various 
structures of the rat brain. 
Nonspecific binding was determined in 
the presence of 10~^ M SCH 23390 and 
10"6 baloperidol respectively. Values 
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Inhibition of l\l SKP 39393 (2 nM) and 
/%/ spiperone (0.25 nM) binding to 
striatal membranes by dopamine agonists 
and ED^q for induction of yawning in rata. 
Values are means - SEM of the data from 
2-4 separate experiments^ 
Compound 
ICjo (nM) 
Dopamine D1 Dopamine D„ Eatio Yawning 
/%/ 
SKP 38393 


















Inhibition of /\] SKP 38393 (2 n*) and 
, /%/ spiperone (0.25 nM) binding to 
striatal membranes by dopamine antago­
nists and ED^q for induction of catalepsy 
in rats. 
Values are mean * SEM of the data from 
2-4 separate experiments. 
IC50 (nM) Catalepsy 
Compound Dopamine D1 Dopamine Dg Ratio ^50 
/^/SKP 38393 /^Й/spiperone D.,/D2 mg/kg 
Haloperidol 89-20 5.5*2.5 16 0. 18 
(+)-Butaclamol 8.5*20 3.7*1.6 2. •3 
Chlorpromazine 162*43 40.5*11 4 2. 3 
(-)-Sulpiride 22,000-1,000 264*105 83 75 
(+)-Sulpiride 28,000*17,000 15 ,000*1,000 1. 9 
Raelopride 100,000 379 264 13 
Reaoxipride 100,000 19 ,000 5. 3 9 
Azaperone 1,000*730 413*170 2. 4 
Azasilane 1,100*410 2 ,300*600 0. 5 
Clozapine 396^204 751* 11 0. 5 65 
Carbidine 9,000*2,700 1 ,500*320 6 20 
SCH 23390 2.3*0.7 2 .500*1100 0. 0009 0. 02 
66 
Discussion 
The results of the present study in confirmation with 
others (4) indicate that /%/ SKP 38393 labels the sites 
which may be designated as the D-1 receptors. Although the 
regional distribution of the D-1 receptors labeled by /% / 
SKP 38393 very closely correlates with that of the D-2 re­
ceptors labeled by /"W spiperone, the functional role of 
these sites remains unknown. Our data, however, indicate 
that these neuroleptics which are potent in competing for 
D-1 receptors are also potent;in inducing catalepsy. Thmsb 
this suggests that the interaction of neuroleptics with D-1 
sites may contribute to their potency in inducing catalepsy. 
This proposition, nevertheless, contradicts the data that 
was obtained in binding studies with /^H/ SKP 23390, where 
the moat potent competitors were thioxanthenes and phenothi-
azines but not butyrophenones (7). However, it should be 
emphasized that /%/ SKP 38393 and /%/ SCH 23390 may label 
distinct states of the D-1 receptor. Therefore, it should 
not be excluded that the blockade of the D-1 high affinity 
state of D-1 receptors by neuroleptics may account for the 
development of catalepsy. On the other hand, our previous 
study (18) as well as many others (2,8,15) have shown that 
the antistereotypic potencies of neuroleptics are highly 
correlated with their potency to displace /hi/ spiperone 
from the D-2 sites suggesting that the antagonism of ste­
reotypy is mediated via the D-2 receptors. The properties dt 
DA receptor agonists to induce yawnings donnot, however* 
correlate with their agonistic potency at the D1 or D2 re­
ceptors. Recent studies have shown that the D-2 receptor can 
exist in two states of high and low affinity for the D-2 re­
ceptor agonists. Analysing the dose response data concerning 
yawning induction and stereotypy, it can be supposed that 
the agonistic D-2 affinity state might be involved in the 
mediation of yawning, whereas the agonistic low affinity 
state seems to mediate a stereotypic response. However, the 
hypothesis remains highly speculative, since at present 
time no direct evidence suggesting the existence of differ­
ent affinity Jtates of the DA receptors under in vivo con­
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DECREASE IS in vivo /^/SPIPERONE BINDING IN 
MOUSE BRAIN AFTER CHRONIC HALOPERIDOL TREATMENT 
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Hormonal Regulation, Tartu University 
Key words: in vivo /%/spiperone binding - chronic 
haloperidol 
Abstract: 
Administration of haloperidol (2.5 mg/kg, i.p.) 
for 21 days to mice resulted in disappearance of in­
hibition of locomotions and in increased cage climb­
ing behaviour induced by DA receptor agonist apomor-
phine 0.1 and 1 mg/kg, respectively, during 2-7 days 
after withdrawal, suggesting the development of DA 
postsynoptic receptor hypersensitivity. Despite the 
sign of behavioural hypersensitivity in these ani­
mals, a decrease in in vivo /%/spiperone binding 
was observed during 2-7 after withdrawal. Reduction 
of /^H/spiperone binding was seen in both structures 
studied: striatum and cortex. Similar results were 
also obtained after acute haloperidol treatment. On 
the basis of these findings, it is proposed that ob­
served decrease in /^H/spiperone binding underin vi­
vo conditions might be caused by partial displace­
ment of radioligand by residual haloperidol still 
present in the cerebral tissues. 
Introduction 
Repented administration of antipsychotic drugs to labo­
ratory nnimiiL» and their subsequent withdrawal induce the 
cerebral dopamine DA receptor hypersensitivity (2,4,11, 18, 
19). After withdrawal from chronic treatment with typical 
neuroleptics, the animals displayed exaggerated stereotypic 
response to apomorphine and an increase in the striatal DA 
receptor sites (D2 sites not linked to the dopamine sensi­
tive adenylate cyclase) identified by in vitro binding tech­
niques using tritiated DA receptor agonists and antagonists 
(2,11,14,16,19). It has been proposed that such prolifera-
of DA receptors that was detected in in vitro binding stud­
ies is favoured by the development of behavioural supersen­
sitivity to the DA receptor agonists in laboratory animals 
or dyskinetic disturbance in the patients chronically trea­
ted with neuroleptics (6,14). Although the studies using in 
vitro binding technique invariably show a significant in­
crease of the D2 receptor binding sites in the striatum ct 
the animals chronically treated with neuroleptics, the in 
vivo binding studies using /^H/spiperone as a ligand give 
less consistent results. 
Thus, Bishoff (1) found an increase in in vivo /"hi/spi­
perone binding in the striatal and hippocampal tissues of 
brain after 21 days of haloperidol treatment and 4 days of 
washout period. Similar results were obtained by Perrero et 
al. (3). In contrast, Saelens et al. (13) reported that the 
chronic administration of haloperidol resulted in a decrease 
in in vivo /%/spiperone binding in the subcortical but not 
in <the cortical structures of the rat brain. The authors in­
terpreted these data in the terms of compensatory reduction 
of the antagodist binding sites and of a complementary in­
crease of the agonist binding sites after chronic haloperi­
dol treatment. 
In the light of these contradictory results, it was 
interesting to re-examine the state of the DA receptor sen­
sitivity in the mice chronically treated with haloperidol 
using both behavioural experiments and in vivo /%/spipercne 
binding techniques. 
Methods 
Male mice weighing 18-22 g were given i.p. single or 
repeated injections of haloperidol 2.5 mg/kg (commercial am­
poules, Gedeon Richter, Hungary) for 21 consequtive days. 
71 _ 
The corresponding control animals received saline injections. 
At different time after chronic haloperidol or saline treat­
ment the animals were randomly divided into groups of 8-12 
mice and taken for behavioural experiments. The animals were 
Injected with 0.1 mg/kg of apomorphine HCl or saline and im­
mediately placed into the individual fotocell chambers for 
the determination of locomotor activity. The locomotor acti­
vity was counted during 30 min after apomorphine injection . 
Another group of mice received 1.0 mg/kg of apomorphine HCl 
and the cage climbing behaviour was determined. The climbing 
behaviour was assessed in the cylindrical cages (12 cm dia., 
15 cm high) with walls surmounted by fine wire mesh. The in­
tensity of climbing behaviour was scored during 1 min at 10 
min intervals of 30 min observation period according to the 
method of Wiloox et al. (21). 6-10 animals from chronic ha­
loperidol or saline groups and the animals from acute halo -
peridol or saline groups were used for the determination of 
in vivo /^H/spiperone binding. The in vivo binding of /"W 
spiperone (Amersham pic., England) was determined according 
to the method of Hdllt at al (5). The animals were given in­
to tail veins 5 ug/kg of /^H/spiperone (spec. act. 16-19 Ci/ 
mmol) and 1.5 hours sacrificed by the cervical dislocation . 
The brains were rapidly removed, striatum and frontal and 
parietal cortex were dissected on the ice-cold plate and af­
ter that weighed. The radioactivity was counted in a LS-6800 
liquid scintillation counter (Beckman, USA), the following 
combustion of the samples in a BTS tissue solubilizer (Beck-
man) at 50°C for 2 hours. For the determination of non-spec­
ific binding the mice in the parallel experiments were giv­
en i.p. haloperidol (10 mg/kg) 30 min before the i.v. injec­
tion of radioligand. 
The statistical analysis of non-parametric data has been 
performed by the Mann-Whitney U-test. All other behavioural 
and binding data were evaluated by the Student's t- test. 
Results 
The chronic treatment of mice with haloperidol resulted 
in considerable modification of the behavioural effects- of 
the UA recuptor agonist apomorphine. 
A.Lthough ". n control animals low doses of apomorphine 
7? 
(0.1 mg/kg) caused a significant reduction of looomozions, 
in chronic haloperidol treated animals apomorphine did not 
induce any inhibition of the locomotor activity within 2-6 
days after withdrawal (Pig. 1). Only on the 10th day after 
withdrawal the inhibitory effect of apomorphine on the lo­
comotion reappeared (Pig. 1). After chronic haloperidol 
treatment the mice exhibited more intense cage climbing in­
duced by apomorphine (1.0 mg/kg) then the control animals 
(Pig. 2). The increased climbing behaviour was observed dull­
ing 2-7 days after the withdrawal of chronic haloperidol 
treatment suggesting the development of the postsynaptic DA 
receptor hypersensitivity. Despite the behavioural signs 
of the DA receptor hypersensitivity in these animals, quite 
a marked inhibition in in vivo /^H/epiperone binding in 
the mouse brain was found (Table 1). This effect was obser­
ved during 2-7 days after withdrawal from chronic haloperi­
dol. On the 10th day after the withdrawal the /%/ spipe­
rone binding tended to increase in the striatal tissues in 
comparison with the control animals; however, the data did 
not reach the level of significance (Table 1). Acute injec­
tion of haloperidol, similar to chronic treatment, also in­
duced a decrease in in vivo /%/spiperone binding in the 
striatum and frontal cortex of the mouse brain (Table 1) . 
The reduction of binding in these animals was seen, however, 
during a shorter period, 2-5 days after haloperidol pre-
treatment. 
Discussion 
The data of the present study, in confirmation to 
those reported by Saelens et al. (13), showed a reduction 
in the in vivo /^H/spiperone binding in the mouse brain af­
ter chronic and acute haloperidol treatment. In addition , 
we detected a decrease in binding not only in striatum but 
also in frontal cortex where /^H/spiperone labels preferen­
tially serotonin 52 receptors (7,9). In our study, we were 
also able to detect the behavioural supersensitivity as re­
vealed by the increased cage climbing behaviour induced by 
the receptor agonist apomorphine in the mice chronically 
treated with haloperidol. These data contradict numerous re­
ports where the proliferation of the D2 receptors deter­
73 
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mined in vitro and the corresponding increased sensitivity 
to the behaviearal effects of the DA receptor agonists al­
ter chronic neuroleptic treatment have been described (2,16, 
19). 
Keeping in view that the properties of the DA recep­
tors are identical in respect to the antagonist affinities 
under in vivo and in vitro conditions (7,8), it can be con-
luded that the observed changes in in vivo /%/spiperone 
binding are due to the partial displacement of the radio­
ligand by residual haloperidol »till present in the cereb­
ral tissues. Äie residual haloperidol masks the increase in 
/•^/spiperone binding that would be expected to occur 4>n 
the basis of many behavioural and binding /-^/spiperone 
The lack of any structural differences in the reduc­
tion of /%/spiperone binding and the decreased binding e-
ven after acute haloperidol treatment observed in our expe­
riments indirectly support this position. The recent study 
of Wan et al. (20) showed that even under in vitro condi­
tions the residual neuroleptic might induce a decrease in 
the affinity of the binding sites in the /"W spiperone 
binding assay. Recently Öhman et al. (12) reported that af­
ter chronic and acute treatment of rate with haloperidol, 
the drug was still present during 2-6 days after withdrawal, 
in the cerebral tissues in concentrations of about 10 ng/g 
per tissue. This concentration of haloperidol seems to be 
sufficient to interfere in the /%/spiperone binding assay 
ender in vivo conditions. These data, however, should be ap­
plied with oaatlon when explaining our data, since conside­
rable differences may exist in the rate of haloperidol eli­
mination between the rat and the mouse cerebral tissues . 
Since /^H/spiperone under in vivo conditions does not dis­
tinguish between the populations of the pre- and postsynap­
tic DA receptors in the striatum, it is not clear which of 
them might be preferentially occupied by the residual neu­
roleptic. Relying on the well-documented data that the in­
hibition of locomotor activity induced by low doses of apo­
morphine is related to the presynaptic VA receptors, where­
as in low (presynaptic) doses haloperi.doi selectively anta­
gonizes this effect of apomorphine (10,1b), it may be pro­
poned that the inability of apomorphine to induce ^^iation 
in mice after chronic haloper j do i i.re'itment, observed in 
Table 1 
Effect of acute or repeated (21 day») treatment with 
Haloperidol (2.5 mg/kg/day, i.p.) on in vivo /^H/epi-
perone binding in mouse striatum and cortex. Results 
are means - SOU expressed in prool per g tissue. N -
number of animals j * - P<0.05; ** - P<0.01 (Student's 
t-test) 
Specific /%/spiperone binding 
Treatment Я (praol • g~1) 
Striatum Cortex 
2nd day after withdrawal 
Control: saline a 7.6 i 1.0 ,5.2 - 0.5 
Haloperidol acute 8 2.4 ± 0.5™ 2.0 - 0.4** 
chronic 10 3.0 ± 0.4™ . « 2.4 - 0.09* 
5th day after withdrawal 
Control: saline 8 8.7 - 1.2 5.0 - 0.8 
Haloperidol acute 8 5.4 ± 0.6* 2.1 - 0.7* 
chronic 10 4.7 t 0.7* 2.6 - 0.l\ 
7th day after withdrawal 
Controlt saline В 8.4 ± 1.2 4.4 ±0.7 
Haloperidol acute 6 7.4 i 0.5 3.9 - 0.6 
chronic 8 5.1 t 0.7* 3.2 i 0.5 
10th day after withdrawal 
Control: saline 6 7.9 i 0.6 4.2 - 0.6 
Haloperidol acute 10 7.8 t 0.6 3.8 ± 0.6 
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Pig. 2. The cage climbing behaviour induced by apomor-
phine (1.0 mg/kg) in mice after withrawal from 
chronic saline (- -) or Haloperidol (- -) 
treatment. Means - SEM of 8-10 animals per 
group. ** - P^O.01 (Mann Whitney U-test). 
77 
the present study, is due to the latereetlon of residual ha-
loperidol with apoaorphine on the presynaptic receptors. 
However, it ia not clear whether the exclusive occupation of 
the presynaptic DA receptors may indeed be reflected by the 
decrease in in vivo /"Wspiperone binding, since the studies 
on the rata with lesions of the ascending nigrostriatal DA-
ergic pathway by 6-hydroxydopamine, which eliminates the 
striatal presynaptic DA receptors, did not reveal any chan -
ges in the striatal in vivo /%/spiperone binding (17). It 
is not excluded that residual haloperidol occupies the DA 
postsynaptic receptors as well as the presynaptic receptors, 
or any other receptors (e.g., serotonin(S-2) receptors), in-
activateds them and thereby prevents the sedative action of 
low dose of apomorphine. 
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THE INFLUENCE OP ИР ON THE BEHAVIOURAL 
EFFECTS OF DOPAMINE RECEPTOR AGONISTS 
AND ANTAGONISTS 
K.Z. Õereaka, G.E. Gebers,  . . Ööpik, 
end A.M. Zharkovsky 
Department of Pharmacology and Laboratory of 
Hormonal Regulation, Tartu State Uni­
versity, Tartu, 202400, Estonia, USSR 
Abstract: 
In experiments on rats and mice the action of 
neuropeptide Pro-Leu-Gly (MIF) on the behavioural ef­
fects of dopamine (DA) receptor agonists and antago­
nists has been studied. It was found that MIF in dose 
1 mg/kg (i.p.) enhanced the yawning behaviour that 
was induced by D2 receptor agonist Ly 171 555 (6.01 
mg/kg, s.c.) in rats. The inhibitory effect of Ly 
171 555 on the locomotions of mice was also enhanced 
by MIF. 
In addition, MIF 0.1 mg/kg diminished the inhi­
bitory effect of the D2 receptor antagonist sulpi­
ride on the locomotions of mice. In contract, MIF in 
doses 0.1-10 mg/kg did not affect the behavioural ef­
fects of selective D1 receptor agonist and antagonist 
or mixed D1/D2 receptor agonists and antagonists.MIF 
in the doses used did not change either the level of 
striatal or mesolimbic DA and its metabolites HVA and 
DOPAC. 
It is proposed that MIF excerts its modulatory 
effect on the DA-ergic neurotransmission allosteric-
ally interacting with the hi^h affinity D2 binding 




Considerable evidence indicates that the hypothalamic 
factor melantrtpin releases the inhibiting hormone (Pro-Leu-
Gly-NHg; MIF), in addition to its endocrine activity it pos­
sesses direct effeote on the central nervous system indep­
endently of their interaction with the hypothalamio-pitui-
tary axis (2,3,4). Among various central actions of MIF the 
best described is its effect on the dopaminergic neurotrans­
mission. The neurochemical analysis of the mechanism of the 
MIF action showed that peptide exerts modulatory effect on 
the dopaminergic neurotransmitter system (2,3,4,5,10,14,19). 
Thus, MIF selectively enhanced the binding affinity of 
the dopamine agonist %-apomorphine to the dopamine recept­
ors, augmented the turnover of dopamine, and inhibited the 
dopamine-sensitive adenylate cyclase activity in the caud­
ate nucleus but did not influence the dopamine uptake, ty­
rosine hydroxylase or dopa-decarboxylase activity (9,18,19, 
20). 
Recent studies have shown that MIF antagonized the ha-
loperidol-induced enhanced /^H/spiroperidol binding in rat 
striatum (2,5,7,10). On the basis of these studies some au­
thors have hypothized the existence of a unique MIF recep­
tor site functionally coupled to the dopamine receptor 
through which MIF might modulate the nigrostriatal dopamin­
ergic neurotransmission (4,5,8,9). 
At present at least two different types of dopamine re­
ceptors have been described (17). These receptors were i-
dentified on the basis cf their linkage to adenylate cyc­
lase. Thus, the dopamine D1 receptor is linked positively to 
adenylate cyclase, and the D2 receptor is independent of or 
even involved in the inhibitory control of this enzyme (17, 
27). In recent studies, the selective agonists and antago­
nists of D1 and D2 receptors have been described (6,16, 21, 
28). In the light of these findings arises a question, which 
of these receptor-'-, subtypes are involved in the effect of 
82 
MIF oa the dopaminergic neurotransmission. Therefore, the 
aim of the present study was to investigate the action of MIF 
in the behavioural effects of the specific D1 and D2 recept­
or agonists and antagonists. 
Materials and Methods 
Experiments were carried out on male rats weighing 200-
300 g and male mice weighing 25-30 g. The animals were kept 
under standard vivarium conditions and they received food 
and water "ad libitum". 
Behavioural Studies 
Locomotor activity was measured in mice placing them in­
to individual cylindrical activity cages (18 cm high, 30 cm 
diameter) each fitted with two photoelectric unite located 2 
cm above the floor and connected with an electromechanical 
counter. The number of counts was determined in a 30 min pe­
riod of observation. Catalepsy was assessed in mice accord — 
ing to the method of Honma, Fukushima (15). Briefly, at va­
rious intervals after drug treatment the animals were placed 
by their forepaws onto the horizontal bar, positioned 4 cm 
above the floor and the time in seconds during which the a-
nimals remained in such a position was recorded. In order to 
assess the stereotypy and yawnings, the rats were placed in­
to individual square plexiglass boxes (15x15x15 cm).The num­
ber of yawning episodes was recorded during a 60 minute test 
using a hand-held counter. The stereotypy was scored on a 
four-point severity scale after a 1 min observation period 
and at every 15 min interval for up to 60 min according to 




Рог carrying out biochemical studies the rats were de­
capitated, brains were rapidly removed and striata were dis­
sected out on the ice. Dopamine (DA) and its metabolites -
homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid 
(DOPAC) were isolated on the columns with Sephadex G-10(Far-
macia, Sweden) and measured spectrofluorimetrically in a 
fluorescence spectrophotometer MPF-2 (Hitachi, Japan) ac­
cording to the method of Early, Leonard (13). 
Drugs 
The following drugs were used: MIF (obtained as a gift 
from the Institute of Pharmacology, Academy of Medical Sci­
ences, Moscow) was dissolved in saline and injected s.c. 20 
min before the test. D1/D2 mixing agonist apomorphine • HCl 
(USSR) was dissolved in saline containing 0.05 % of ascorb­
ic acid as an antioxydant and injected s.c. in the neck re­
gion of animals; the specific D2 receptor agonist Ly 171555 
(qiunpirrole HCl, gift of Eli Lilly Co., Indianopolis, USA) 
was dissolved in saline and injected s.c. ; the D2 receptor 
anagonist sulpiride (commercial ampoules "Eglonyl") was di­
luted to the appropriate volume with saline and injected i. 
p. in a dose 100 mg/kg; the D1 specific antagonist SCH23390 
(as a gift of Schering, Corp., Bloomfeld, USA) and halope­
ridol (Janssen Farmaceutica, Beerse, Belgium) were dissolved 
in a minimal amount of acetic acid, further diluted with 
saline and injected i.p, 
Statistics 
The results were expressed as means ± SEM. Рог statis" 
tical calculations the 1-way analysis of variance (ANOVA) 
followed by Student's test or Dunnett's t-test were used. 
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Results 
MIF in doses 0.1-10.0 mg/kg given alone failed to af­
fect locomotions in mice within 90 min after treatment. The 
specific D2 receptor agonist Ly 171555 induced the inhibi­
tion of locomotions in mice. This effect of Ly 171 555 was 
observed even after very low doses of Ly 171 555 (0.01mg/kg). 
MIF (1 mg/kg) enhanced this effect of Ly 171 555 on locomo­
tions. The effect of MIF was not dose-dependent and in a 
higher dose (10 mg/kg) disappeared (Fig. 1), MIF also anta­
gonized the inhibition of the locomotions induced by sulpi­
ride (Fig. 2). In contrast, MIF did not change the behavi­
oural stimulation induced by SKF 38 393 or the catalepsy 
induced by 5CH 233 390. MIF did not either change the halo-
peridol-induced catalepsy in mice. 
Similar results were obtained in experiments on rats. 
Thus, the MIF potentiated by Ly 171 555-induced yawnings 
(Fig. 3) but did not influence either the haloperidol-ind -
used catalepsy (Table 1) or the apomorphine-induced stereo­
typy (data not shown). MIF also did not change the levels of 
DA and ite metabolites HVA and DOPAC in the striatal and me-
solimbic tissues of the rat brain (Table 2). 
Discussion 
Recent studies have shown that Ly 171 555 and sulpi­
ride selectively interacted with the D2 receptors, whereas 
SKF 38 393 and SCH 23390 posseseed agonistic and antagonis­
tic properties respectively at D1 receptors (6,11,16,21,27, 
28). In contrast, apomorphine and haloperidol counteract 
with both types of receptors, D1 and D2 (6,11,16,25). 
The results obtained in the present study show that MIF po­
tentiates the behavioural effects of the selective D2 re­
ceptor agonist Ly 171 555 and abolishes the behavioural ef­
fects the specific D2 receptor agonist sulpiride and which 
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Table 1 
Bffeet of MIF on the catalepsy induced by 
haloderidol and SCH 23390 in Mice. The da­
ta are means - 5EM in groups of 8-10 ani­
mals. Catalepsy was measured 60 min after 
haloperidol and 30 min after SCH 23390 
treatment. 
Catalepsy (sec.) 
Drug (mg/kg) Haloperidol SCH 23390 





229 - 15 
187 - 29 
178 - 36 
157 - 22 
43 - 6 
4 4 - 9  
4 1 - 7  
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does not affect'the behavioural changes induced by D1 re­
ceptor agonists and antagonists. These data suggest thatДО 
selectively counteracts with the D2 receptors probably fcyln-
creasing their sensitivity to the D2 receptor agonists. The 
previous binding studies as well as the data obtained in 
our laboratory suggest that this modulatory effect of MI? 
is not dependent on the direct interaction of IUP with the 
D2 sites (6,8,9). Most probably, the enhancing effect at 1 ? 
on dopaminergic neurotransmission is due to the allosteric 
interaction of the MIF-sensitive binding sites with the D2 
receptors. The previous studies have shown that the inhibi­
tion of locomotor activity or yawning behaviour induced by 
low doses of dopamine receptor agonists are mediated via se­
lective activation of presynaptic (auto) receptors of the 
- D2 type (12,22). According to some other authors, these ef­
fects are mediated via the D2 postsynaptic receptor» dis­
tinct from those which induce stereotypy or catalepsy (6, 
22). Binding studies have also revealed that at least two 
subtypes or affinity states of the D2 receptor might exist 
within the CNS (27,28). The data of the present study also 
indicate that a novel D2 receptor agonist Ly 171 555 in the 
doses used selectively activates a distinct subtype (or af­
finity state) of the D2 receptors which is involved in the 
induction of yawnings and inhibition of locomotions. This 
proposition ie further supported by the failure of MI? to 
change the stereotypy and catalepsy induced by apoeorphine 
and haloperidol, respectively. On the basis of these results 
it might be proposed that MIF exerts its modulatory effect 
allosterically interacting with the high affinity Wbtype 
of the D2 receptor which represents probably a preflgMptio 
(auto) receptor. 
Finally, the modulatory effect of MIF appears only in 
the narrow range of doaes. The higher doses of MIF failed to 
change the behavioural effects of Ly 171 555 and sulpiride. 
The ineffectiveness of high doses of MIF is difficult to ex­
plain. Previous studies have shown that the transport of a 
close analogue of MIF Tyr-MIF into brain may be inhibited 
by Tyr-MIF itself (1). Sych^self-inhibition may also occur 
in the case of MIF. Furthe^Sre, high concentrations of MIF 
may inhibit the binding of peptide to its receptors result­
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THE PARiMTHRS OF СЯОИСУЗТОКПИЯ (CCfc-8) RECEPTORS 
IN ШШЖТ 1RAIN STRUCTURES OF THE RAT 
A. Soo saar, E. Vasar, A. Lang 
Laboratory of Peychopharmacology 
Abstract: 
The binding specificity of ^H-CCK-8 was deter­
mined in rat brain structures. The analysis of the 
association and dissociation experiments at 23°C 
revealed an apparent two-site fit of the binding da­
ta In the all rat brain regions examined. The pret-
reatment of brain membranes at 37°C caused a comple­
te loss of slower dissociation component of ^H-CCK-8 
binding. According to the Scatchard analysis the pre-
treatment of the membranes at 37°C did not alter 
the density of the CCK-8 receptors, but the affini­
ty of the CCK-8 binding sites was decreased 1,5-2 
times. The highest amount of the CCK-8 binding sites 
was in mesolimbic area, somewhat lower in frontal 
cortex and the lowest in brainstem. The calculation 
of the 1 values for different CCK-related pepti -
des and CCK-antagonisto also revealed differences 
between the brain structures. The results of this 
study demonstrate the disparity of the CCK-8 binding 
sites in different brain structures. The CCK-8 bin­
ding sites differ in their affinity for different 
ligands and in the density in the different brain 
areas. 
INTRODUCTION 
Cholecystokinin octapeptide (CCK-8) is an important 
gastrointestinal hormone with well established neuronal ac­
tivity. The peptide is located throughout brain in a cha­
racteristic distribution (1,5), parallelled to large extent 
by the distribution of its specific binding sites (в.ТЗ). 
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Recent electrophysiological and biochemical studies have 
demonstrated the existence of different population of CCK-8 
receptors in the brain. CCK-8 in low concentrations inhi­
bits the activity of pyramidal cells In hippocampus,whereas 
the higher concentrations "are needed for exciting of these 
cells (2,7). In the radioligand binding studies is demons­
trated the presence of central and peripheral CCK-8 recep­
tors in the brain (3). Several authors have shown the bi -
phasic dissociation of the radiolabelled CCK-8 from the bin­
ding sites in cerebral cortex (14,11). The hypothesis of 
this disparity of CCK-8 receptors may be supported by the 
fact that CCK-8 has different neurochemical interactions in 
the brain structures. For example, in the mesolimbic area 
CCK-8 has strict interaction with dopamine, while in cereb­
ral cortex and hippocampus it is located ir. the same neu­
rons with the major inhibitory neurotransmitter GABA (4,6). 
The main task of the present work was to characterize the 
CCK-8 binding sites in different brain structures for revea­
ling the possible disparity in the properties of the CCK-8 
receptors in brain structures. 
MATERIALS AND METHODS 
The experiments were performed on male rats, weighing 
200-250 g. During the following decapitation (between 9 and 
12 a.m.) the whole brain was rapidly removed. The brain 
structures (frontal cortex, mesolimbic area, striatum, hip­
pocampus, brainstem) were dissected on ice and the membra­
nes were prepared according to the method of Saito et al. 
(1981). The brain structures from six rats were pooled, ho­
mogenized in 10 volumes of 50 mM TrigHCl buffer ( pH 7,4 et 
4°C) using a motor driven teflon-glass (Potter-S) homogeni-
zer for 10 strokes. The homogenate was centrifuged at37000x 
g for 15 min, resuspended in the same volume of buffer and 
recentrifuged for 15 min. The pellet was then homogenized 
in the standard incubation buffer, consisting of the fol­
lowing: HEPES 10 mM, NaCl 130 mM, KCl 5 mM, MgClg 5 mM , 
EDTANa2 1 mM, bovine serum albumine 0,5 mg per 1 ml (pH 6,8 
at 24°C). The binding experiments were carried out in poly­
propylene tubes (1,5 ml), which routinely received 50 jil of 
^H-CCK-8 (60-80 Ci/mmole, Amersham International, U.K., fi­
nal concentration 0,05-1,5 mM), 50 ц1 of various concentra­
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tions of peptides or drugs, and 400 jil of freshly prepared' 
brain membranes. In the majority of experiments the membra­
nes were preincubated for 25 min at 23°C with peptides or 
drugs, and after that the radiolabelled CCK-8 was added in­
to polypropylene tubes and the samples were carefully mixed. 
The incubation procedure was terminated by rapid oentrifu-
gation in a Beckman microfuge 12 (11000x g) for 3 min at 
room temperature. The supernatants were aspirated, and the 
pellets were washed with 1 ml of incubation buffer. ZtShe 
tips of tubes were cut and dropped Into the scintillation 
vials. The radioactivity was counted by liquid scintilla­
tion spectrometry (Beckman LS' 6800) in the Bray cocktail. 
The counting efficiency for tritium was 40-5256. The epeci-, 
fic binding of ^H-CCK-8 was defined as the difference bet­
ween the degree of binding in the absence and the presence 
of 100 nM of caerulein sulfated. Saturation curves were 
analyzed according to the method of Scatchard (1949). The 
1 50 values for drugs and peptides were obtained using the 
log-probit analysis. 
The following drugs were used in the experiments: cae­
rulein sulfated, caerulein desulfated (Par-mitalis Carlo Br-
ba, Italy), CCK-4 (I.C.I.,U.K.), tifluadom(S&ndot, Switzer­
land), proglumide (Rotta Research Labs, Italy),pentagastrin 
(Semites, USSR), haloperidol (Gedeon Richter» Hungary). 
RESULTS 
The binding of ^H-CCK-8 to the rat brain membranes was 
monitored at 23°C for various time intervals. The -associ­
ation of radioligand reached to the equilibrium during 60 
min in the mesolimbic area and hippocampus, and during 75 
min in frontal cortex and striatum. The binding was stable 
for 4 hr. The binding of JH-CCK-8 to brain membranes was 
linear between 1 and 10 mg of original tissue/ assay . For 
routine assay 3-4 original tissue/assay was used . After 
reaching the state of equilibium the binding of the radio-
labelled CCK-8 was reversed by adding 100 nM of caerulein 
sulfated. The analysis of the association experiment bv In 
(Beq/Beq-Bt) (Beq, the specific binding at equilibrium; Et, 
the specific binding at indicated time) vs. time showed the 
observed association rate constant (K . ). It was 0.0200 
. -1 . _i fbs 
nun in front.1! cortex, 0,02o min in mesolimbic area, 
0,0?4P min ^ in striatum and 0,0220 mi:i ^ in hippocampus. 
97 
13 
The. analysis of the dissociation experiment by the plot In 
(Bt/Bo) (Bt, the specific binding at the indicated time; Bo, 
the specific binding at the start of the dissociation expe­
riment) vs. time showed a biphasic curve. The higher disso­
ciation rate constant (K_1f) was 0,0121 min-1 in frontal 
cortex, 0,0152 min-1 in mesolimbic area and 0,0183 min-1 in 
striatum. The slower dissociation rate constant (k_1g) was 
0,0070 min-1 in frontal cortex, 0,0056 min-1 in mesolimbic 
area and 0,0059 min-1 in striatum. Using the relationship 
K+1= (Koba-K_i8):L, in which L represents the concentration 
of ^H-CCK, was calculated the association rate constant(ta-
ble 1). The equilibrium dissociation constant (K^) was cal­
culated from the ratio of the dissociation and association 
rate constants (K_^;K+1) (table 1). The pretreatment of 
brain membranes at 37°C caused the complete loss of the 
slower dissociating component of the JH-CCK-8 binding. The 
results of kinetic experiments demonstrated that the affi­
nity of the CCK-8 binding sites was higher in the mesolim­
bic area than in the other forebrain structures. In satura-
3 tion experiments with increasing concentrations of H-CCK-8. 
(0,05-1,5 nM) the specific binding was proportional to the 
amount of the radioligand used. The concentrations of the 
radiolabelled CCK-8 over 1 nM completely saturated the CCK-8 
binding sites in the forebrain (figure). The Scatchard plot 
was linear in all brain structures studied in the present 
experiment (table 2). Pretreatment of brain membranes at 
37°C decreased evidently the affinity of the CCK-8 binding 
sites to the radiolabelled ССЁ-8. The change was more marked 
in striatum (see also table 1, the difference between two 
kinetic constants in striatum). These results evidently de­
monstrate that the pretreatment of brain membranes at 37°C -
does not reduce the number of the CCK-8 binding sites, but 
obviously decreases their affinity. 
In.table 3 are shown the mean values of binding experi­
ments with different brain structures. The amount of the 
CCK-8 binding sites in rat brain was the highest in the me­
solimbic area. The number of the CCK-8 binding sites was 
somewhat lower in frontal cortex and striatum, whereas in 
hippocampus and brainstem it was significantly lower if com­
pared to the mesolimbic area (table 3). The calculation of 
this ICcjQ values for different CCK-related peptides and CCK 


















Figure. A saturation experiment showing the binding of 
several concentrations df ^H-CCK-8 (0,08-1,5 nM) 
to rat brain membranes at 23°G for 120 min. The 
specific binding of ^H-CCK-8 is presented in fi­
gure. The differences between total (in absence 
of 100 nM caerulein) and nonspecific (in presence 
100 nM caerulein) binding is defined as specific 
binding. Frontal cortex ~ЯЛг I Mesolimbic area 
—W~ I Striatum —Щ— 
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The effect of pretreatment at 37°C on ^H-CCK-8 
binding in different forebrain atructurea 
I« ———~ "*' •" 'il 
Brain 23°C pretoM*ttwnt 37°б ' 
structure Ka Kd ^»ax 
»«*..•!• — 1» . . «t • II... I ,u -
Frontal cortex 0,35*0,04 25 0,65*8.<У+ 
Meeolimbic area 0,25-0,02 6,35*0,87 0,3*40,03+* 6,6<^0»30 
Striatum 0,36*0,04 5,70*0,30 0,30*0,05*4" 6,40*0,26 
I I . ..——— 
Kd - diaaociation constant (n*); - density of binding 
eitea pmolea/g tiaeue. + - p<0,05i *+ - p<0,Ql ( Student 'a 
t-teet). 
Table 3 
The binding parameters of ^H-CCK-B in different 
brain regiona 
Brain structure n (n*) BIMT(pmole8/g tiaeue) 
Frontal cortex 12 0,35*0,04 4,59*0,20 
Meaoliebio area 12 0,32*0,05 5,21*0,22 
Striatum 12 0,33*0,04 4,88*0,23 
Hippocampus 6 0,35*0,05 2,25*0,25 
Brainstem 3 0,3(1*0,05 0,59*0,08 
n - number of experiments; Кд - dissociation constant 
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structures (table 4). Sulfated caerulein similarily dis­
placed -hl-CCK-8 from binding sites, whereas the action of 
CCK-4 was more pronounced in the mesolimbic area and stria­
tum. The effect of pentagastrin was also the highest in the 
mesolombic area and striatum, but in hippocampus and frontal 
it had somewhat lower affinity (table 4).The CCK antagonist 
proglumide had the most significant effect in hippocampus, 
in hippocampus the action of proglumide was approximately 4 
times weaker. The other CCK antagonist tifluadom displaced 
similarly radiolabeled CCK-8 from binding sites in all 
structures studied. The comparison of the effect of caeru­
lein and tifluadom after the pretreatment of brain membra­
nes at 37°C revealed significant changes in the action of 
tifluadom, although the effect of caerulein remained un­
changed (table 5). The affinity of tifluadom was increased 
1,5-2 times after pretreatment at 37°C. The binding sites of 
CCK-8 in pancreas were completely lost after the pretreat­
ment of membranes at 37°C. It was shown in our previous ex­
periments that the repeated administration of haloperidol 
caused significant changes in the behavioural effects of 
caerulein, Ein agonist of CCK-8 receptors. The inhibiting ef­
fects of caerulein became obviously weaker or the stimula­
ting effects of caerulein became evident after repeated ha­
loperidol treatment (12,13). The effects of long-term halo­
peridol treatment (0,5 mg/kg daily, during 15 days) on the 
^H-CCK-8 binding in different brain structures in different 
experiments were compared. The results of different studies 
are quite contradicting: the repeated haloperidol adminis­
tration might increase as well as decrease the number of 
the CCK-8 binding sites in brain. The calculation of the 
mean values of 6 independent experiments has not demonstra­
ted statistically evident differences in the ^H-CCK-8 bin­
ding after haloperidol treatment (table 6). The pretreatment 
of brain membranes at 37°C also did not reveal the differen­
ces between the long-term administration of saline and ha­
loperidol. 
DISCUSSION 
The results of the present study have supported the 
idea about the disparity of the CCK-8 binding sites in the 
brnin. The dissociation experiments have revealed the bj -
phasic, nature of the Ч1-ССК-8 dissociation from binding 
sites. Pretreatment of brnin membranes at <7°C results in 
10', 
a complete loss of slowly (high-affinity) dissociating bin­
ding sites. This finding is in agreement with the studies 
of Wennogle et al. (1985) and Sekiguchi, Moroji(1986). How­
ever, the Scatcberd analysis have not confirmed the view­
point of Wenaogle et al. (1985) that the pretreatment of 
brain membranea at 37°C significantly reduces the nuaber eft 
the CCK-8 binding sites. In reality, auch a procedure evi­
dently reduces the affinity of tbe CCK-8 binding sites, but 
not their density in forebrain structures. It seems possible 
that the interconvertible оonforaational states of the CCKß 
binding sites exist in the brain structure and the pre­
treatment of brain membranes at 37°C converts all binding 
sites into the low-affinity state. The ratio of hig)*- and, 
low-affinity binding sites for CCK-8 seems to be different 
in forebrain structures. Study of competition curves of dif­
ferent CCK-related peptides and CCK antagonists in diffe­
rent brain regions also supports the idea of heterogenity 
of the CCK-8 binding sites in brain. CCK-4 has 2,5-3 times 
higher affinity for subcortical CCK-8 binding sites (meso-
limbic area and striatum) if compared with the binding si­
tes in frontal cortex. Proglumide, an antagonist of thel 
CCK-8 receptors, has very weak affinity for the CCK-8 bin-* 
ding sites in brain, although the disparity also exists in 
the action of proglumide. Proglumide has approximately 3,5 
times lower affinity for the CCK-8 binding sites in stri­
atum if compared to the binding sites in hippocampus. The 
differences in the action of the CCK- antagonists may be 
also linked to the uneven distribution of the CCK-8 binding 
sites in the rat brain. The density of this CCK-8 binding 
sites is the highest in mesolimbic area, somewhat lower in 
striatum and frontal cortex, whereas in hippocampus their 
density is approximately 2,5 times and in- brainstem 10 ti­
mes lower than in the mesolimbic region of rat brain. 
Despite the profound changes in the action of caeru­
lein after long-term haloperidol treatment (12,13) we fail 
to find any statistically significant changes in the densi­
ty of the CCK-8 binding sites after 15 days haloperidol ad­
ministration. It seems possible that a long-term haloperi­
dol treatment separates the inhibiting and activating CCK-8 
receptors, increasing relatively the amount of activating 
CCK-8 binding sites. Unfortunately in the binding studies 
it is impossible to separate these different binding sites. 
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In conclusion, the present study demonstrates the dis­
parity of the CCK-8 binding sites in the brain. The diffe­
rences in the properties of the CCK-8 binding sites are re­
lated to the uneven distribution of the CCK-8 binding sites 
in brain structures (mesolimbic area striatum=frontal cor­
tex hippocampus brainstem), to the different distribution 
and properties of interconvertible conformational states 
(faster and lower dissociating component) of this CCK-8 
binding sites in forebrain and to the disparity In the af­
finity of the CÖK-8-ergic Uganda to the CCK-8 binding ei­
tea in different brain regions. 
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NEUROLEPTIC -r CHOLECySTOKININ INTERACTION: THE 
INVOLVEMENT OF Na-PUMP 
E. Vaaar, M. Zilmer, A. Soosaar 
Laboratory of Psychopharmacology, Department of 
Biochemistry. 
Abstract: 
The experiments on male rats have shown the re­
duction of sodium pump activity in the diffe­
rent brain structures after administration of 
caerulein (10 ug/kg), an agonist of CCK-8 re­
ceptors, and proglumide (1 mg/kg),an antagonist 
of CCK-8. The simultaneous administration of 
caerulein and prqglumide completely reversed 
the decreasing effect of both compounds. The 
acute treatment of haloperidol (0,5 mg/kg) also 
decreased the activity of Na - pump, but after 
repeated (during 15 days) treatment the action 
of haloperidol was more pronounced. Acute and 
chronic proglumide medication antagonized the 
effect of repeated haloperidol treatment. In 
binding studies concomitant administration of 
haloperidol and proglumide reversed completely 
the effect of haloperidol on the -%-CCK-8 bin­
ding in different forebrain structures.lt seema 
probable that the reduced activity of Na - pump 
and its decreased cooperativity with Na+ is 
playing an evident role in the development of 
depolarization inactivation of dopaminergic neu­
rones after administration of the CCK - 8 ago­
nists and neuroleptic drugs. 
INTRODUCTION " 
The intravenous and iontophoretic administration of 
cholecystokinin octapeptide (CCK-8) were observed to activa­
te dopamine cells to the point that they developed a state 
jog 
of apparent depolarization inactivation (3). Similar effect 
was found after repeated administration of antipsychotic 
drugs. Their long-term application leads to the inactivity 
of the great majority of midbrain dopamine-containing cells 
(1,6). This inactivity has been reported to be also due to 
the state of tonic depolarization inactivation of neurons 
(2). Proglumide, an antagonist of CCK-8 receptors reverses 
completely the inactivation of dopamine cells induced by 
CCK-8 or repeated neuroleptic treatment (3,4). It seems ve­
ry probable that CCK-8 is mediating the effect of a long-
term neuroleptic treatment on dopamine cells activity, but 
the biochemical nature of this phenomenon remains still un­
known. The aim of the present investigation was to study 
the role of Na+/K+ATPaae in the neuroleptic-CCK-8 inter­
action. It is well-known that sodium pump is the key factor 
in the regulation of the resting potential of neurorls memb­
rane. The decreased activity of this enzyme may be the rea­
son for the depolarization inactivation of nerve cells. Si­
multaneously with the change^ in aodium pump activity the 
parameters of ^H-CCK-8 binding were studied after the long-
term treatment of haloperidol and proglumide. 
METHODS 
The experiments were performed on female albino rats, 
weighing 200-240 g. In acute experiments CCK-8 agonist- cae­
rulein (10 Jig/kg s.o., Parmitalia Carlo Erba, Italy) was 
injected 15 min, proglumide (1 mg/kg i.p., Rotta Pharma­
ceutic!, Italy) 20 min and haloperidol (0,5 mg/kg i.p. , 
Gedeon Richter, Hungary) 60 min before the decapitation of 
animals. The brain was rapidly removed from the skull and 
the brain structures (frontal cortex, nucleus accumbens, 
striatum, hippocampus and substantia nigra-ventral tegmen­
tal area) were prepared on ice. The brain structures of 
acute experiments were used for the purifying of Na/K^ATPa-
se. 
In the second part of the experiment haloperidol (0,5 
mg/kg i.p. daily) and proglumide (10 mg/kg i.p. daily)were 
injected alone or simultaneously during 15 days. On the 
15th day 1 hr after the last injection of haloperidol or 
SO min after proglumide the rats were killed by the deca­
pitation. In one group of animals, receiving only halo -
110 
peridol, the acute injection of proglumide (1 mg/kg i..p. ) 
waa done 20 min before the decapitation of rata on the 15th 
day. The braina of the animals, receiving repeated halope-
didol or proglumide treatments, were uaed for the Na+/K+AT­
Pase studies as well for the measurement of ^H-CCK-8 bin­
ding. 
Na+/K+ATPase activity (pmole P^/ng protein per min)waa 
assayed with 5 mM ATP-Tris, 100 mM NaCl, 20 mM KC12 and 30 
mM imidazole buffer, pH 7,4 at 37°C. The Hill's coefficient 
(n*a+) were calculated from Hill plot.v 
^H-CCK-8 binding experiments were performed in frontal 
; cortex, nucleus accumbens audi striatum. For binding studies 
the modified method of Praleaean (5) wee uaed. Briefly, the 
brain structures of 5 rats were pooled, homogenized in 10 
volumes of TrisHCl buffer (50 mM, pH 7,4 at 20°C).The memb­
ranes were centrifuged twice (35000xg during 15 mln). The 
incubation medium was the followlngi HepesKOH (10 mM,pH 6,8 
at 20°C), 120 mM NaCl, 5 mM KCl, 5 mM М«С12, 1 mM BDTANa2 
and bovine serum albumine (1 mg per 2 ml of Incubation me­
dium) . The washed membranes were•homogenized In Incubation 
buffer (10 mg original tissue in ml). The homogenized memb-
rsnee were preincubated during 30 min (at 23°C) in the in­
cubation medium: 3 parallels without and 3 parallels with 
Qaeruleln-(100 nM). Then ^H-CCK-8 (60-85 Ci/mmole, Amersham 
International, Ü.K., 0.08-1.5 nM) waa added into the incu­
bation mixture and the membranes were incubated during 120 
»In at 23°C. The binding waa stopped by rapid centrifuga-
tion (11000xg during 3 min). The supernatant waa discarded 
and pellet washed two timea with 1 ml ice-cold incubation 
buffer and cut into vials. Radioactivity waa counted in the 
Bray acintillation cocktail in a Beckman LS 6800 ( counting 
efficacy 50-53 %). The results of binding experiments were 
analyzed using Scatchard analysis. 
RESULTS 
Acute administration of caerulein (10 ug/kg) decreased 
the activity of the Na-pump as well n^ for Na+ in frontal 
cortex, nucleus accumbens and hippocampus (table l).Proglu­
mide (1 mg/kg) caused the decrease of the Na+/K+ATPase ac­
tivity and n^ for Na+ in all structures studied. The coad­
ministration of proglumide and caerulein completely atte­
nuated the changes in the Na-rpump activity and in particu­
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lar the changes of n^a caused Ъу both druga(table 1).Acute 
administration of haloperidol (0,5 mg/kg) reduced the acti­
vity of Na-pump in frontal cortex and hippocampus, whereas 
the nH for Na+ was decreased in frontal oortex, nucleus ac­
cumbens and striatum (table 2). Long-term haloperidol treat­
ment evoked the more pronounced reduction in the parameters: 
of Na+/KTATPase activity in comparison with acute treatment. 
The repeated treatment of proglumide (10 mg/kg) caused the 
significant reduction of the Na-pump activity in all struc-
turfes studied. However, the acute or long-term administra­
tion of proglumide antagonized all the changes in Ha+/K+AT­
Pase actively caused by long-term haloperidol (table 2). A 
parallel study of the parameters of ^H-CCK-8 binding revea­
led the statistically evident decrease of the ^H-CCK-8 bin­
ding sites in frontal cortex after long-term treatment of 
haboperidol, while in the other structures it caused an in­
significant increase in their number (table 3). Long- term 
administration of proglumide (10 mg/kg) enhanced the affi­
nity of the CCK-8 binding sites in nucleus accumbens and 
striatum, the density of the CCK-8 sites was reduced in nuc­
leus accumbens. The coadministration of haloperidol and 
proglumide antagonized the haloperidol caused changes, but 
potentiated the effects of long-term proglumide medication 
(table 3). 
DISCUSSION 
The acute administration of caerulein, an agonist of 
the CCK-8 receptors, reduces obviously the activity of the 
Na-pump in forebrain structures. Simultaneous administra­
tion of proglumide, an antagonist of CCK-8, completely 
blocks the action of caerulein. A similar reduction of the 
Na+/K+ATPase activity is found after acute treatment of ha­
loperidol, but it was more pronounced after long-term admi­
nistration of haloperidol. The acute or repeated simultane­
ous administration of proglumide with haloperidol complete­
ly reverses the effect of haloperidol on the Na-pump acti­
vity. It seems very probable that the inhibiting action of 
long-term haloperidol treatment on the Na-pump activity is 
medicated through the CCK-8-ergic mechanisms. This opinion 
is supported by radioligand studies. The long-term halope­
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of the ^H-COK-8 binding sites In frontal cortex and subcor­
tical structures, whereas coadministration of proglumifie 
with haloperidol completely attenuates the effect of halo­
peridol on •'н-ССК-в binding. The results of the present in­
vestigation are consistent with the studies of Bunneу et al. 
(3,4), revealing the similar antagonism of proglumide agptosl 
the depolarization inactivation of dopamlne-containing neu­
rons by CCK-8 and longterm haloperidol medication. There is 
existing possibility that haloperidol by blocking dopamlneg-
receptors increases the release of CCK-8 from neurons. Inc­
reased stimulation of the CCK-8 receptors ldads to the dec­
rease of the Na-pump activity1 in different brain structure» 
The reduced activity and cooperativity with Na+ of this en4 
zyme seems to play an evident role in the development oil 
depolarization inactivation of dopaminergic neurones in -
duced by the CCK-8 agonists and neuroleptic drugs. 
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AK ELEVATED PLUS-MAZE: A POSSIBLE TOOL FOR 
DETECTING STATE AND TRAIT ANXIETY IS RODENTS 
J. Harre, R.-чА. Kiiret, «. Poid, and Ь. R8go 
Department of Pharmacology 
ABSTRACT: 
The effect of anxiolytic and anxiogenie - drugs 
(diazepam and DUG* respectively) on the exploratory 
activity of mice in two models was compared. It waa 
shown that an elevated plus-maze model had signifi­
cant advantage in respect to simple open field model. 
Mice and rats selected according to their explorato­
ry activity in elevated plus-maze as anxiops and non-
anxious animals had dissimilar neurochemical charac­
teristics. Namely, anxious animals had significantly 
lower number of central benzodiazepine binding sites 
in frontal cortex, but not in cerebellum.lt ie conc­
luded that animal selection procedures may represent 
a possibility of creation of models for analysing 
the predisposition toward feeling anxious in some 
individuals. 
INTRODUCTION 
Pharmacotherapy of pathological mental states depends 
upon our understanding of the neurobiologioal mechanisms 
underlying euch conditions. It has been shown that for the 
study of anxiety mechanisms angiogenic compounds besides 
anxiolytics are also useful ('32). A wide variety of animal 
models for anxiety have been pursued and several explorato­
ry behaviour paradigms are most widely exploited (9). The 
simplest system for measuring exploratory activity is place­
ment of the animal in an unfamiliar open field.However, the 
sedative effect of anxiolytics will produce much noise in 
this trivial test (9). Recently a new apparatus - an eleva­
ted plus-maze - wa.s described and validated for detecting 
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the effects of anxiolytic and anxiogenie drugs in rat( 22,-
24). We compared the influence of a classical anxiolytic 
diazepam and a potent anxiogenie compound DMCM (methyl-6,7-
dimethoxy-4-ethyl-^-carboline-3-carboxylate) on the beha­
viour of mice in a combined open field/hole board apparatus 
and in an elevated plus-maze. 
Psychologists distinguish between "state" and "trait" 
anxiety. State anxiety refers to the anxiety felt at a par­
ticular moment; trait anxiety implies the predisposition 
toward feeling anxious as a personality trait.Persons with 
high trait anxiety are more likely to feel anxious at any 
instant because they have a lowered threshold for the in­
duction of fear and tension (17). The efforts of experi­
mental psychobiology are mainly directed to the elucidati­
on of the substrate of anxiety in state anxiety models(ex-
position of subjects to acute stressful events)whereas the 
trait anxiety paradigms have received a quite poor atten­
tion. However, it is suggested that the anxiety, experien­
ced by animals, is not too dissimilar from such human psyc­
hic condition (14). It is possible to select experimental 
animals according to their individual behavioral peculia­
rities related to anxiety and to find some neurochemical 
correlates (21,27). 
The compounds, acting at central benzodiazepine recep­
tors, have clear relations to anxiety states(2,30). There­
fore, it is logical to seek for the differences in benzo­
diazepine receptor characteristics in the CMS of animals, 
selected according to their more or less "anxious", behavi­
our in novel environment. 
MATERIALS AND METHODS 
Male white laboratory mice and rats weighing 22-25 g 
and 200-220 g respectively were used in this study.The ani­
mals were housed 40-45 (mice) or 15-20 (rats) per cage.The 
exploratory activity of mice was measured in open field 
and in plus-maze model. Mice were placed singly into the 
open field/hole board apparatus (30x30x18 cm,16 equal sec­
tors, 16 holes with diameter 1,4 cm) and observed during 
the first 2 min. The number of crossed sectors, head-dips 
and roars was counted. The plus-maze consisted of two open 
arms (2I'x5 cm) and two enclosed arms (??x5x15 cm) with an 
118 
open roof. The maze waa elevated to the height of 25 cm.To 
determine the exploratory activity in the open part of the 
maze the pair of open arms was divided into 7 equal sec­
tors. During a 4 min test session tire latency period of the 
first open part entry, the number of sectors crossed in 
open arms, and the total time spent in open arms were mea­
sured. To begin the experiment nd.ce were placed at the 
centre of the plus-naze, facing one of the enclosed arms. 
Locomotor activity was registered in a inultieage photocell 
motor activity meter. Kach cage of the actometer wae a cy­
linder with the height of 20 cm and diameter of 30 cm. Lo­
comotor activity of mice was measured for a period of 30 
min. DHCM (Schering AO, West Berlin) and diazepam(Seduxen, 
Gedeon Richter, Hungary) were administered intraperitone-
ally 15 or 30 min before, the experiment respectively. 
In the plus-maze selection experiments, mice and rats 
first were observed in a plus-maze for 4 min. The appara­
tus for rats was in principle similar to the one for mice 
except that the size was different (50x10 cm and 50x10x40 
cm for the open and enclosed arms respectively). The ani­
mals were killed by decapitation immediately after the be­
havioural test. Dissected and homogenized brain regions 
were washed twice in TRIS-HC1 buffer by centrifugation 
(48 000 g for 20 min) and resuspenaion. The binding was 
carried out in the presence of 0,125-8 nM of ^H- flunitra-
zepam (spec. act. 81 Ci/mmol, Ainersham Radiochemicals ) 
using a total incubation volume of 500 pi. To determine 
nonspecific binding unlabelled flunitrazepam (10 uM, Hoff­
mann - La Roche, Basel) was added. After 60 min incubation 
at 0°C the reaction was stopped by rapid filtration over 
the GF/B (Whatman, England) filters. Specific binding was 
calculated by subtracting the non-specific from total bin­
ding at each given radioactivity concentration. 
The analysis of variance and Student's t-test for pai­
red observations were used to determine statistical signi­
ficance. 
RESULTS AND DISCUSSION 
Anxiogenie p-carbolines can aggravate the behavioral 
responses to stressful events or induce fear by itself (5, 
12,23,25). As shown in Table 1, administration of a potent 
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Table 1 
The effect of DMCM and diazepam on the exploratory activity 
of mice in a combined open field/hole board apparatus • and 
on the locomotor activity in a multicage photocell motor 
activity meter. Reaulta are expressed as a mean - SEM. 
Treatment Crossed N of N of Actometer 
(mg/kg) sectors rears head-dips counts 
Vehicle 19,8+2,8 4,5+1,1 13,5+1,9 160+15 
DMCM 0.5 20.2+3.0 4.3+0.7 17.0+2.5 151+25 
1.0 16.7+3.9 2.8+0.7 13.4+1.9 154+17 
1.5 10.1+3.5 1.8+0. 4X 12.1+2.1 ' 130+20 
2.0 5.3+2.5xx 0.8+0.2^ 5.3-1.4XX 100+19х 
Diazepam 0.5 24.1+2.1 6.5+1.2 17.7+1.6 181+16 
1.0 21.0+2.6 8.7+1.9 13.9+2.2 160+17 
1.5 15.2+2.9 3.1+0.8 13.1+2.3 120+17 
2.0 10.4+2.1 x  1.2+0.7 X  9.5+1-7 х* 95+15 х  
DMCM 0.5 + 
diazepam 0.75 23.3+4-3 4.8+0.4 13-4t2.0 155+20 
DMCM 1.0 + 
diazepam 0.75 27.8+2.0 x +  10.1+2.0 X + +19.2+1.9 152+18 
x - F<0.05 as compared to vehicle treated animals 
xx - P<0.01 as compared to vehicle treated animals 
+ - P<0.05 as compared to DMCM 1.0 treated animals 
++ - P<0.01 as compared to DMCM 1.0 treated animals 
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anxiogenie drug DMCM decreased all parameters of explorato­
ry behaviour observed in open field only in quite high do­
ses. The number of rears seems to be the most sensitive be­
havioral pattern to DMCM. The doses of DMCM which signifi­
cantly attenuated the number of crossed sectors and head -
dips in mice also lowered the basal locomotor activity. 
We were not able to demonstrate the anxiolytic effect 
of diazepam in our open field experiments. The activating 
effect of little doses of diazepam did not reach signi -
ficance and in doses 1.5 mg/kg and more diazepam had a se­
dative effect. This discrepancy with the results, obtained 
by several authors, may be related to a different strain of 
the mice used or to a high baseline level of the response 
(8,28). In any case, such results are not unexpected,as the 
data from open field experiments are quite inconsistent(13)1 
It haa been pointed out that the qualities of the test arena 
are also important in this paradigm. 
Using the borderline doses of DMCM and diazepam toget­
her we found that this combination can lead to a signifi­
cant increase in exploratory behaviour.(Table 1). Benzodia­
zepine inverse agonists can support information processing 
(33). Possibly a combination of anxiolysis and intensified 
information processing gives rise to such enhanced explora­
tion. It is apparent that, if this is the case, distinct 
primary targets may be involved for the action of benzodia­
zepine agonists and inverse agonists. 
Animals display fear not with regard to novelty per se but 
when they are prevented from responsing normally to the new 
conditions (20).There is no unique relationship between lo­
comotor activity and fear (1), and rodents will walk around 
a test arena to explore it or to escape from if or both(11X 
Therefore, an apparatus for detecting anxiety state has to 
be somewhat more artificial and complicated than a simple 
open field. An elevated plus-maze has recently been valida­
ted for testing anxiety in rats (22,24). In our experiments 
with mice (Table 2) administration of DMCM had clear dose 
dependent attenuating effect on all the parameters registe­
red. The conflict in the behaviour of animals between the 
exploration drive and "agarophobia" was obvious, but requi­
res a detailed etholo^ical analysis. Nevertheless, the pa­
rameters used as the latency period of the first open part 




The effect' of DMCM and diazepam on the exploratory acti­
vity of mice in an elevated plus-ease. Results are expressed 













Vehicle 28+ 6 20.6+2.4 54+ 7 
DMCM 0.5 39+ 7 14.9+4.2 39+ 4 
1.0 55+13 8.4+3. 5х 29+ 5X 
1.5 89+21х 5.3+2.8xx 17+ 6n 
2.0 95+20* 4.2+2.0xx 15+ 5х* 
Diazepam 0.5 25+ 6 22.2+2.7 54+ 9 
1.0 21+ 4 24.7+3.1 48+ 8 
1.5 16+ 3 33.5+3.4x 94+ 9х* 
2.0 27+ 9 25.3+2.6 70+10 
DMCM 1.5 + 
diazepam 0.75 33+ 8+ 18.3+3.6+ 46+ 8+ 
x - P < 0.05 as compared to vehicle treated animals 
xx - P< 0.01 as compered to vehicle treated animals 
+ - P < 0.05 ее compared to DMCM 1.5 treated animals 
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Table 3 
Selection experiment according to the exploratory acti­
vity of mice in an elevated plus-maze. Results are expres­
sed as a mean + SEM. 
Group N of Latency of N of open Total time 
animals first open arm sectors spent in 









Non-anxious 12 13 + 2= 31*3 + 4.1х 78 + 13 х  
subgroup 
Anxious 12 209 + 18 a +  8.4 + 2.4 X +  15 + 3 m  
subgroup 
x - P <0.05 as compared to total group 
xx - P < 0.01 as compared to total group 
+ - P < 0.01 as compared to non-anxious subgroup 
Table 4 
Selection experiment according to the exploratory acti -
vity of rats in an elevated plus-maze. Results are expres­
sed as a mean + SEM. 
Group N of Latency of N of open Total time 
animals first open arm sectors spent in 
part entry crossed open arms 
Total 39 36 + 10 9.4 + 0.6 50 + 4 
Non-anxious 5 7 + 1x 14.6 + ол** 79 + 7
xx 
subgroup 
Anxious 5 102 + 23 x+ 3.2 + 1.0 х" 13 + 
subgroup 
x - P < 0.05 as compared to total group 
xx - P4. 0.01 as compared to total group 




Scathard analysis of saturation data of ^H-flunitrazepam 
binding in mice selected according to their exploratory ac­
tivity in an elevated plus-maze. Each value is the mean +SEM 
of three separate experiments. 
Animal H-flunitrazepam binding 
group ^max (^mol/mS protein) KD (nM) 
с В R E В R A L C O R T E X  
Non-anxious 1410 + 90 1.41 + 0.12 
Anxious 1070 + 70 х  1.46 + 0.18 
с E R E В E L L U M 







+ 90 1.43 + 0.24 
x - P<0.05 as compared to non-anxious subgroup 
Table 6 
Scatchard analysis of saturation data of ^H-flunitrazepam 
binding in rats selected according to their exploratory ac­
tivity in an elevated plus-maze. Each value is the mean 4SEM 
of three separate experiments. 
, 
Animal H-flunitrazepam binding 
group ®max protein) Ky (nM) 
C E R E B R A L  с о : R T E X 
Fori- anxious. 1290 + 40 1 .55 + 0.09 
Anxious 1100 + 30 х  1 .54 + 0.11 
CEREBELLUM 
Hon-anxious 920 + 40 1 .27 + 0.19 
Anxious 870 + 20 1 .54 + 0.21 
x - P<0.05 as compared to non-anxious subgroup 
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tal time spent in open arms, are also acceptable for indi­
cation of anxious behaviour, if using non-sedative doses of 
drug (see Table 1, actometer counts). It seems that this 
model is more reliable for measuring the action of angioge­
nics, because the basal activity of rodents was usually 
high. However, the positive effect of diazepam on explora­
tory activity was also observable, confirming the results 
of Pellow et al, obtained on rats (22). 
The anxiogenic effect of DMCM on the exploratory beha­
viour of mice in the plus-maze was completely abolished by 
the administration of diazepam in the dose ( 0.75 mg / kg ) 
without any measurable action by itself. It seems that DMCM 
and diazepam exert their effect on the exploratory activity 
in this model through a common site of action,probably cent­
ral benzodiazepine receptors. 
In several works carried out with rodents,animals have 
been selected according to their distinct spontaneous(3,26, 
31) or drug-induced (7,21,27) behaviour. Such selection ex­
periments have given some worthful preliminary information 
about the neurochemical basis of diversity in animal beha­
viour (21,26,27,31). It has been suggested that the animals' 
general level of fear, determined by its past history, will 
also interact with exploratory behaviour (16). As the vari­
ability in the exploratory activity of mice and rats in an 
elevated plus-maze was quite high we decided to separate 
the most extremistic individuals into subgroups for the 
following binding studies. As shown in Tables 3 and 4, it 
was possible to select group-housed mice and rate according 
to their more or less "anxious" spontaneous exploratory be­
haviour in this test. We termed these selected subgroups as 
non-anxious or anxious, because their spontaneous behaviou­
ral characteristics resembled the effects of anxiolytics 
and anxiogenics respectively. 
In vitro ^H-flunitrazepam binding in the cerebral cc -
tex and cerebellum of non-anxious rodents demonstrated v.!-
milar differences both in mice and rats. Namely, the number 
of benzodiazepine binding sites was significant'у lower Ir-
cerebral cortex but not in the cerebellum of ai rious ani­
mals (Tables 5 and 6). No reliable differences in tiw bin­
ding affinity were found between subgroups. 
The present finding that the rodents which di:-:Xay 
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re anxious behaviour in plus-maze have lower benzodiazepine 
receptor density in cerebral cortex might be interpreted in 
two ways. First, if the exposition to stressful events would! 
decrease ^H-flunitrasepam binding as proposed by Medina et 
al (18), decreased exploratory activity and lower benzodia­
zepine receptor density in cerebral cortex have to be re­
garded as the reflection of the reaction to an acute envi­
ronmental change. However, there is also evidence that ac­
ute stress situation may cause rapid increase in brain ben­
zodiazepine receptor binding (19) and enhance the activity 
of chloride ion channel function (15,29). Therefore,we pre­
fer another possible interpretation. It seems that the neu­
rochemical correlates of behavioural differences in the an­
xiety - measuring model used reflect the individual trait 
to have a lowered threshold for the induction of fear. Such 
em individual trait might be either formed in social inter­
actions er determined genetically or is,most probably,influ­
enced by both named factors. There is no sufficient data 
available to make decisions about the genetic aspects of 
the observed problem yet. At the aaae time, several works 
indicate that durable lifetime stressors cause neurochemi­
cal alterations. Chronic administration of anxiogenic Q-oar-
bolines induced long-lasting proconflict effect in rats(6), 
and decreased the density of low-affinity GABA receptors 
(probably coupled with benzodiazepine receptors) in diffe­
rent rat brain areas (4). Furthermore, chronic psychogenic 
stress suppressed the exploratory activity of rats in open 
field and decreased the density of benzodiazepine receptors 
in cerebral cortex (10). We have recently demonstrated that 
the mice, more sensitive to the sedative action of baclofen, 
a GABAJJ receptor agonist, were also more sensitive to the 
sedative action'of diazepam and had a lower density of ben­
zodiazepine receptors in the forebrain (27). Baclofen-res-
ponders displayed more anxious behaviour in an elevated 
plus-maze than baclofen-nonresponders (our unpublished da­
ta). It seems that social interactions in the animal popu­
lations were responsible for these behavioural and neuro­
chemical differences, because separation of baclofen-res-
ponders and baclofen-nonresponders into distinct cages abo­
lished all differences between subgroups. However, the real 
origin of distinct exploratory behaviour in the plus - maze 
model remains to be clarified in further experiments, so as 
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the possibility to use animal «election in plus-maze for de­
tecting trait anxiety. 
In some conditions stress situations do not influenae 
basal %-flunitrazepam binding but the potency of chloride 
ions to ehhance it (15). As our binding experiments were 
performed in TRIS-HC1 buffer there is a possibility that 
our results do reflect not the differences Id the bensodia-
zepine receptor oharacteristies of belA.vio«Mllj selected 
animals but the differences in the chloride channel func­
tion. For elucidation of the role of Ни GiM/bensodiasegd» 
ne/Cl~ loaophore receptor complex in the anxiety treit aere 
complete studies are required* 
CONCLUSIONS 
1. It is possible to use an elevated plw-saice es an 
exploratory behaviour model of anxiety in miee. This model 
is more reliable than a trivial open Held test. 
2. Mice and rats, divided according to their explore# 
tory activity into anxious and non-anxious subgroups- have 
distinct benzodiazepine receptor bindlag properties in ce­
rebral cortex. 
3. The possibility of creation of trait anxiety --mo­
dels using T selection procedures in exploratory beha­
viour paradigms is suggested. 
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_ THE ADAPTATION PROBLEM IN PHARMACOLOGY 
L. Nurmand 
Department of Pharmacology 
Abstracts 
As every drug affects normal (or pathological) 
homeostasis certain adaptive-compensatory react -
ions of varying intensity develop practically to 
any drug administered. The adaptive-ooapensatory 
reactions can be observed on molecular-cellular and 
on systematic levels. These reactions play a cert» 
ain role in formation of drug action, in develop­
ment of adverse reactions and abstinence or with -
drawal syndrome. In consequence, the drug action 
is a complex of immediate functional changes deve­
loped as a result of drug-receptor interaction and 
of adaptive-compensatory reactions aimed at neu­
tralizing them. 
The investigation of these reactions is of 
great importance in assay of new drugs. These re­
actions must also be considered in the course of 
determination of rational drugs, therapeutic regi­
mens and tactics. 
Adaptation to changing external and internal factors is 
an important property of living matter. It is a factor de­
termining the persistence and evolution of Life. 
In the course of phylogenesis all species have deve­
loped most effective machanisms, protecting them against va>-
rious factors affecting homeostasis. Drugs (xenobiotics)are 
potent homeostasis affecting agents. A drug (remedium or 
poison) is defined as a substance, which, if introduced, 
changes the functions of a living organism, i.e. affects the 
physiologic (or pathologic) homeostasis. Several defence 
mechanisms are activated in order to guarantee the etabili-
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ty pf int*r*»l medium. These mechanisms are pointed at the 
delivery of the organise from drug and at the recovery of 
the affected functions. 
The adaptive reaction« of the organism to foreign sub-
gtancea. The reewtione-aimed at the elimination of foreign 
substances are as follows: 
- Biotransformation: transformation of a lipid soluble 
substance into water-soluble matabolites, which can be ea­
sily eliminated. This transformation is carried out by spe­
cific or nonspecific enxyme systems, such as microsomal mo-
nooxygenase system containing cytochrome P^q, several 
transferases (glucuronyl transferase, acetyltransferase)etc. 
(14,18). 
- Immunological defence: specific binding of the xeno-
biotic to antibodies or to complementary binding sites. The 
foreign substance itself seldom acts as an antigene, usu -
ally the drug complex or its metabolite with plasma or tis­
sue proteins act as antigenes. The formed antigene-antibody 
complexes poorly penetrate into tissues, they do not react 
with receptors and are finally transformed and excreted (11, 
12). As the formation of antibodies needs some time, this 
compensatory mechanism works especially in case of repeated 
exposure to drugs. 
- The excretion of a foreign substance or its water so­
luble metabolites via kidneys, gut or other ways. 
The reactions aimed at the recovery of the affected 
functions are carried out by the common homeostasis main­
taining mechanisms, functioning on the molecular, cellu­
lar, organic or systemic levels. On the molecular level the 
most widely investigated reactions are the receptor sensi -
tivity and/or the endogenic ligand turnover changes as the 
adaptation to receptor agonists or antagonists. So, the re­
ceptor stimulation by an agonist is followed by an adapt­
ive inhibition of ligand turnover and a decrease of receptor 
sensitivity (cholinomimetics, dopaminomimeties) (1, 9, 15). 
The receptor blockade by an antagonist is followed by the 
enhancement of ligand turnover and the hypersensitivity of 
the receptors (neuroleptics, cholinergic, adrenergic, hist-
aminergic, etc. blocking agents (5,6,7,10, 15,16) ). The en­
hancement of ligand release (indirect acting adrenomimetics) 
lowers the receptor sensitivity, the decrease of ligand re­
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lease (antiadrenergic drugs) Is followed by the receptor hy­
persensitivity (1,3). These reactions are realized mainly 
by physiologic feed-back mechanisms. 
On systemic level, the homeostasis is maintained by the 
common reciprocal regulatory mechanisms. A majority of the 
functions are regulated by at least two contrary acting mech­
anisms. Such regulating systems as sympathetic and parasymp­
athetic nervous systems, sleep-alertness, nociceptive and an­
tinociceptive, pressor and depressor, coagulating and anti -
coagulating systems, the hypothalamic liberins and statins , 
enzyme activators and inhibitors, etc. are well known. In 
case a drug causes a functional shift in one or another di­
rection, immediately the opposite mechanisms are activated . 
The drug action can be neutralized also by feedback mecha­
nisms working on different levels. The adaptive-compensatory 
reactions are well demonstrated in the endocrine system - a 
prolonged administration of any hormone or its synthetic an­
alogue depresses the secretion of the endocrine gland ( cor­
ticosteroids, thyroxine, sexual hormones, etc.). It is based 
on the inhibition of hypophysär tropines or on the hypothal­
amic liberins' release. A long-term administration of anti­
coagulants is finally followed by an increase in blood coa­
gulation, and vice versa. Several drugs which are metabolized 
by microsomal enzymes, cause the enzyme induction (14). This 
enhances the metabolism of the drug used as well as that of 
many other drugs. The use of hypotensive drugs having diffe­
rent mechanisms of action can be followed by the compensato­
ry activation of pressor mechanisms, as e.g., the use of hy­
pertensive drugs with their opposites. The changes in body 
fluid volume or osmotic pressure cause compensatory changes 
in the activity of the renin-angiotensine system or vasopres­
sin. 
The role of adaptive-compensatory reactions in formatim 
of drug action and adverse reactions. The adaptive-compen -
satory reactions developing practically to any drug adminis-
tred, modify their action. It can be postulated that drug 
action is a complex of the immediate functional changes de­
veloped as a result of the drug-receptor interaction and of 
the adaptive-compensatory reactions aimed at neutralizing 
them. The role of these components can be different depend -
ing on a drug, its dose, duration of administration and on 
the peculiarities of the organism. Usually, the effect of 
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the adaptive-compensatory reactions is not of great import­
ance, but in some cases it is decisive. Рог instance, the os­
motic diuretics changing the plasma osmotic parameters cau­
sed a compensatory increase in the diuresis. The adaptive -
compensatory reactions can be the factors terminating the 
drug action as in the cases of ethanol (2) and barbiturates 
(17). It is shown that the recovery after these drugs occurs 
at much higher drug blood levels than at the onset of the 
actions. The adaptive reactions play an important part in 
the development of tolerance to many different drugs (neuro­
leptics, tranquillizers, barbiturates, opiates, etc.) (2, 4, 
17). The tolerance does not diminish the drug effectiveness, 
but also complies to the correct dosage and drug schedule. 
Adaptation to drug action can be the main mechanism of ad­
verse reactions (the tardive dyscinesia during neuroleptic 
therapy) (13). The adaptive-compensatory reactions are of 
determining importance in the development of the abstinence-
syndrome in drug addicts and in the withdrawal symptoms in 
the case of an abrupt termination of long-lasting cures. It 
is well known that the abstinence syndrome developed in al­
cohol, morphine, cocaine, barbiturate, amphetamine addicts is 
generally opposite to the main actions of the drugs used (2, 
19), it points significantly at its compensatory character . 
The interruption or termination of a long-lasting drug cure 
can be followed by certain withdrawal reactions. In this case 
activation of the primarily depressed symptoms or the occur­
rence of the opposite effects can be observed. Such syndroms 
are, for instance, as follows: the adrenal cortex insuffi­
ciency and the activation of inflammation after an abrupt 
termination of glycocorticoid therapy; hypertension after 
the administration of hypotensive drugs, stenocardial attacks 
after use of nitrites; the increase of coagulation and the 
occurrence of thrombosis after anticoagulant therapy; the es­
tivation of psychotic symptomatics after having neuroleptics; 
increased anxiety after the effect of tranquillizers, night­
mares after using barbiturates; increased appetite after ad­
ministration of anorexigenes; hypovitaminoais after massive 
doses of vitamins (especially ascorbic acid). 
The adaptive-compensatory reactions and the phannaco-fee-
rapeutical tactics. Any pathologic process can be described 
as a complex consisting of a pathogenetic factor induced 
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changes in homeostasis (i.e., the pathogenesis) and adapt­
ive compensatory reactions against them (i.e., sanogenesis). 
The therapy can be pointed either at the depression of the 
patogenesis or at the enhancement of sanogenesis. .In most 
cases the therapy is aimed at the depression lof the patho -
genesis (the contraria contrariis curantur principle), al­
though by itself, the therapy can be ethiotropic, symptomat­
ic or pathogenetic. The drug action is the opposite to the 
influence of the pathogenetic factor, and thus supporting 
sanogenesis. The adaptive-compensatory reactions to the Aug 
action in this case can cause therapeutical complications (1, 
5,13) producing several untoward effects. 
There can also be a principally different approach to 
therapy: the drag effect is in some way similar to the ac­
tion of the pathogenetic factor (the similia simllibus curan­
tur principle). The common effect of the pathogenetic factor 
and of the drug potentiates the adaptive mechanism's activi­
ty (i.e., the sanogenesis): in this case the untoward ef­
fects are not of such a great importance. There are but few 
examples of this approach: the analgetic effect of local ir­
ritant drugs, the immunostimulant effects of "biogenic-stim­
ulants", enzyme induction by phenobarbital in treatment of 
the icterus of the newborn, etc. can be explained this way. 
It is supposed that the therapeutic effectiveness of antide­
pressant drugs in depression treatment (3,13), also that of 
neuroleptics and apomorphine in schizophrenia treatment are 
based on analogous mechanisms (6). 
To sum it up, the adaptive-compensatory reactions of 
various intensity develop practically to any drug. These re­
actions can be of importance in formation of drug action and 
in adverse effects occurring during or after drug treatment 
(tolerance, eide effects, abstinence or withdrawal syndrome). 
The- investigation of these reactions is of great signific­
ance in the assay of new drugs. The adaptive-compensatory re­
actions must also be considered in the course of rational 
drug choice and determination of therapeutic regimen and tao-
tics. 
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CÖRONOPHARMACOLOGICAL ASPECTS OP PHHUBUT 
M. Otter 
Department of Pharmacology 
Abstract: 
It wae shown that there are time-dependent 
dally variations of pharmacological (behavioural 
and biochemical) effects of phenibut. The deprima-
tive effects of phenibut on spontaneous locomotor 
activity, threshold of agression, coordination of 
movements on rota-rod are notable at 12.00. The no­
otropic, antihypoxLc and anticonvulsant effects are 
strong at midnight, the antiamnestic effects by the 
low level of amnestic functions. The efficiency of 
phenibut is minimal at 18.00 when toxicity is the 
highest. It can be concluded that the Variations cf 
nootropic activity depend on the daily variations 
of biochemical effects (ratio of DA striatum, con­
centration of с AMP in blood) of phenibut. 
Introduction 
Nootropic drugs, such as phenibut, are considered to 
act on the integrative functions of the central nervous sys­
tem, learning and memory, to ameliorate the ageing brain 
processes and organic brain syndromes (1). An elevation of 
the ATP-turnover in the brain and some other processes sug­
gested a possible stimulation of synaptic transmission by 
the compound. Based on this assumption, experiments were 
made on phenibut, a centrally acting derivative, employed 
clinically for about 20 years as a brain activating drug for 
- the treatment of acute and chronic impairment of brain funo-
^tions (7,8) 
Phenibut has certain nootropic (antihypoxic, antitoxic 
138 
and antiamnestic) properties. Myorelaxing sedative proper­
ties characteristic to tranquillizers have been stated in ex­
periments on animals. Marked tranquillizing "effects could be 
observed in asthenic and alcohol abstinence patients. Phe­
nibut is an agonist of GABAg receptors giving the increase 
of dopamine (DA) and DA metabolites in animal brain. 
Numerous investigators have demonstrated the presence 
of diural rhythmic changes in catecholamine and GABA con­
tent in the mice brain (2,5,9,10). Rhythmical variation in 
neurotransmitter contents produce the rhythmical variations 
of pharmacological effects of phenibut. 
The present report makes an attempt to summarize the 
results of the recent experiments performed in our labora­
tory to demonstrate the presence of time-dependent daily 
rhythms in the behavioural and biochemical effects of phe­
nibut. 
Material and Methods 
Male and female white mice averaging 25 - 2 g in weight 
were used. Pour weeks prior to each series of studies the 
animals were kept in a cage at a nearly constant temperature 
(20°C). The mice were given food and water ad libidum and 
they were exposed to 12:12 hr regimen of alterating dark­
ness and artificial light. The light phase ran daily from 
07.00 to 19.00. To determine circadian rhythms, the experi­
ments were carried out on groups of mice consisting of 8-10 
animals at 06.00, 12.00, 18.00 and 24.00 respectively inwia-
ter months. Phenibut (50 and 100 mg/kg) was administered in-
traperitoneally. The animals were put into experiments 60 
min after injection. ' 
For behavioural studies were used: the determination of 
spontaneous motility »as tested by means of a photoelectric 
actometer, emotionality was determined using the electric-
pain test, coordinating activity - using rota-rod and the in­
fluence of the drug by rectale temperature (6). 
In order to determine the special nootropic activity of 
phenibut, three possible test procedures were carried out: 
swimming test at 5° C; antihypoxic effect (the model of hy­
poxic hypoxia) test; active avoidance responses' test in a 
classical shuttlebox of lighted and dark sections (4). In se-
18* 
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parate experiments, the coadministration of phenibut and co-
razol was used for determining the interactions. The chro-
notoxicity of phenibut was also studied. 
As to the biochemical studies, the concentration of 
dopamine (DA) and its main metabolite DOPAC were determined 
spectrofluorimetrically by the method described by Early 
and Leonard. Finally, a circadian-phase-dependency in cyc­
lic AMP content in the blood of mice was found. 
The statistical significance of the differences bet­
ween the mean values was calculated by the Student's un­
paired t-teat. 
Results and Discussion 
In our experiments at least three aspects of the diur­
nal action of phenibut were studied: the action of intrape­
ritoneal, its administration in pase of behavioural effects, 
specific nootropic effects and biochemical effects on the 
dopamine content in brain and cyclic AMP content in blood. 
In the area of behavioural testing, the spontaneous cir-
cadian cycle in untreated mice was compared with the beha­
vioural response to 50 and 100 mg/kg of phenibut I.P. as de­
termined at 6-hour intervals over a 24-hour period under na> 
mal lighting conditions, using separate groups of mice at 
each point (Table 1). 
Distinct, apparently circadian rhythms were detected. 
During control studies, in which saline was injected, the 
mice showed almost continuous active locomotion during the 
dark period, but displayed a relatively low and interrupted 
activity during the light period. Phenibut injection in­
duced the sedation of mice, which depended on the time of 
administration. The ratio of locomotion depression between 
each time period was 4:1. At 12.00 the effect exceeded 5 
times that of the diurnal mean, being minimal at 18.00. 
Table 2 indicates a similar decrease of the effects of 
rectal temperature of mice under the phenibut administration. 
Despite the decreased spontaneous locomotion, the phenibut-
-treatedmice showed increased coordination and strength on 
the rota-tod and swimming test by 5° C. 
The rate of appearance of small anxielytic, tranquili­
zer effect of phenibut at different time moments was not 
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significant. However, the increased pain sensitivity was 
correlated with the increased aggressiveness of mice (Table 
1 ) .  
Table 2 shows the difference in the duration of 
life of mice by corazol-induced convulsions during a 24-h 
period. After injection, especially at 00.00 and during the 
whole dark period, the effect of phenibut remains high, At 
00.00 all the mice remained alive. 
Clinical feedback caused us to examine the diurnal va­
riation of protective effects on animal brain. Hypoxic 
hypoxia model was used. As expected, the antihypoxic effect 
was parallel to the lowering of rectal temperature. 
In both cases the effect was maximal after injection 
at 00.00 during the dark period. 
An avoidance-learned response was recorded when the 
mouse moved to the other side of the shuttle-box during the 
5esec warning period preceding the shock. 
During the initial learning phase, the animals were 
submitted daily to one session in the shuttle-box in morn­
ing at 08.00 and another session in the afternoon at 19.00. 
In the case of nontreated mice, the memory processes were 
better at 19.00 and worse at 08.00. Phenibut seemed to be ac­
tive when memory processes were impaired at 08.00. The dif­
ferences between treatment were significant in the 100mg/kg 
phenibut-treated groups at 08.00. The duration of being in 
dark section was significantly lower.This may depend on the 
higher pain sensitivity of animals. 
After a few preliminary trials we decided to take a 
phenibut dose of 850 mg/kg i.p. for the determination of 
toxicity. Lethality was the highest at 18.00 (Table 2). The 
chronotoxicity (or chronopathology) defined as the rhythmic 
variations in the toxic effects and lethality of animals de­
pends on phase differences in rhythms of 24 hours, e.g., in 
metabolic pathways and processes at various hierarchies of 
biological organization. Relatively high motility, heart 
frequence and diuresis, the activity of certain hepatic (tug-
-metabolizingenzymes occur during the dark period. It is 
possible that these circumstances play a certain role in the 
low toxicity of phenibut during the night time. The data in 
the table reveal that the anticonvulsant effects of pheni­
but after corazol administration are higher during the dark 
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Table 2 
Time course of phenibut (50,100 mg/kg) effects 
(mean*SEM group of 10 mice) 60 min after i.p. adminis­
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Previous research concerning the pharmacological pro­
file of phenibut has demonstrated that in the case of mice 
acute administration enables to increase the brain levels ctf 
dopamine and of its major metabolites, 3,4-dihydroxyphenyl-
acetic acid (DOPAC) and homovanillic acid (HVA) which both 
are reliable indicators of intraneuronal dopamine synthesis 
(7). 
A marked phenibut-induced rhythm could be observed in 
the levels of dopamine and DOPAC rodent striatal contents 
within a 24-hour period. The mean values indicate that the 
content is higher in the mornings and lower at daytime. A 
comparative phasing of their rhythms and those of typical 
motor activity of rodents reveals that the maximum phenibut 
induced DA levels correspond to the animals' activity, high 
pain sensitivity and aggressive behaviour. The striatal con­
tent of i)A seems to be inversely proportional to the pheni­
but (850 mg/kg) induced lethality of mice. During daytime, 
the lethality was significantly lower than the diurnal mean. 
Previous studies have demonstrated the increase of the 
AMP content under some psychoterapic agents. The increase of 
the cyclic AMP content could be induced by the blockade of 
GABA receptors or by the inhibition of GABA synthesis (3). 
On the öther hand, phenibut was capable to modify the 
cyclic adenosine monophosphate (cAMP) content in blood.- In 
line with these data, behavioural studies have evidenced 
that over compound phenibut increase motor activity during 
morning period when the content of cAMP is high. 
Conclusion 
It may be said in conclusion that the central behaviou­
ral and some physiological effects of phenibut can be ex­
plained by its action upon the daily varying concentration 
and the turnover of neurotransmitters (including DA) and it 
may likewise be related to its action on biochemical ef­
fects in blood. During morning hours when the synthesis of 
DA and GABA has increased, may occur the increase of the ac­
tivating effects of phenibut on the memory processes and the 
effects of depressive agents may diminish. 
At the end of the light period at 18.00 the inhibiting 
effects of phenibut prevail. The phenibut-inducedztoxi city 
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was maximal and antihypoxic effects were minimal. 
Any drug, e.g. phenibut, is capable of producing dif­
ferent effects depending on its biological timing. 
Several circadian metabolic rhythms at cellular level 
are synchronized by the circadian pattern of neurotransmit­
ters' secretion functioning as a pacemaker. It is clear that 
those numerous pharmacokinetic, pharmacodynamic and endoge­
nous neurobiological changes have contributed to the circ­
adian alteration in the effects of phenibut. Daily changes 
in the phenibut action may have certain clinical implica­
tion. 
Attempts have already been made to chrono-optimize the 
use of pharmacologic agents. For example, if patients, like 
rats, are most susceptible to the effects of phenibut ( be­
neficial or toxic) when asleep this pattern suggests daily 
dosing in the mornings rather than at bedtime, as is a com­
mon clinical practice now. Such timing may be additionally 
beneficial if coupled with smaller doses of nootropics than 
normally used, provided that they are clinically effective. 
References 
1. Apud J.A., Masotto С., Racagni G. New perspectives in 
the mechanisms of action of nootropic drugs // Xlth In­
ternational Congress on Nootropic Drugs and Organic B^ain 
Syndrome. - Rome, Oct. 14, 1983. - P. 48-56. 
2. Lemmer В., Berger $. Diurnal rhythm in the central dop­
amine turnover in the rat// Naunyn-Schmiedeberg's Arch 
Pharmacol. - 1978; - Vol. 303. - P. 257-261. 
3. Mao C., Guidotti A., Costa E. Effect of GABA on cAMP con­
tent// Naunyn-Schmiedeberg's Arch. Pharmacol. - 1975. 
P. 289-369. 
4. Valzelli L., Tomašikova S. Difference in Learning and 
Retention by Albino-Swiss Mice. Part 1: Effect of Pyri-
tinol// Meth. and Find. Exptl. Clin. Pharmacol. - 1985.-
Vol. 7., N 10. - P. 515-517. 
5. Бигалов Ф.И., Векслер Я.И. Суточные ритмы ферментов ме­
таболизма гаша-аминомасляной кислоты. //В сб.: Хроно­
биология и хронопатология. - М., 1981. - С. 46. 
6. Гацура В.В. Методы первичного фармакологического иссле­
146 
дования биологически активных веществ. - М., 1974. 
7. НарковскиР A.M., Алликметс Л.Х., Мехилане Л.С. Место фе-
нибута среди психотропных препаратов. У/В сб.: Механизм 
действия и клиника производных гамма-аминомасляний кис­
лоты. Уч. ааи. ТГУ, -  687. - Тарту, 1984. - С. 5-16. 
8. Мехилане Л.С., Васар В.Э. Спектр клинического действия 
фенибута. //В сб.: Механизм действия и клиника производ­
ных гамма-аминомасляной кислоты. Уч. зап. ТГУ, - 687.-
Тарту, 1984. - С. II2-I23. 
9. Оттер М.Я., Нурманд Л.В. Сезонные колебания содержания 
катехоламинов в мозге белых крыс. //Бголл. эксп. биол.мед, 
- 1980. - т. 29. - С. 215-217. 
10. Розанов В.А. Сезонные изменения в системе гамма- акино-
масляной кислоты головного мозга мышей. // Украинский 
биохимический яурнал. - 1982. - т. 54. - I. - С. 36-40. 
1.47 
ПЕРИФЕРИЧЕСКИЕ МЕСТА СВЯЗЫВАНИЯ БЕНЗОДИАЗЕПИНОВ: 
ФУНКЦИОНАЛЬНЫЕ РЕЦЕПТОРЫ ИДИ АКЦЕПТОРЫ 
Л.Ряго, В.Саано, М.Ряти, А. Адояан 
Р е з ю м е  
Связывающее место бензодиазепинов (БД) центрального ти­
па, часто называемое также бензодиазепинов™ рецепторов, яв­
ляется интегральным звеном комплекса рецептора ГАЖд-хлорно-
го канала в мозге млекопитающих, через которое бензодиазепи-
ны и небензодиазепиновые вещества позитивно или негативно ал-
лостерически модулируют функции хлорного канала со всеми по­
следующими характерными фармакологическими эффектами. Пока 
БД рецепторы не найдены вне ЦНС. В противоположность цент­
ральным БД рецепторам места связывания БД периферического ти­
па широко распространены во многих органах и тканях, а также 
в ЦНС. Несмотря на то, что периферические места связывания 
БД известны уже десять лет, главное внимание исследователей 
было сосредоточено, в основном, на центральных местах связы­
вания БД. Однако в последние годы достигнут определенный ус­
пех в выяснении множества" функций и свойств периферических 
мест связывания БД. В обзоре описано распределение, развитие, 
физиологическая регуляция и функции, а также проблема сущест­
вования возможных эндогенных и экзогенных лигандов перифери­
ческих мест связывания БД. В свете этих данных обсуждается 
принадлежность этих мест связывания к функциональным рецепто­
рам. 
БИОХИМИЧЕСКАЯ И ПОВЕДЕНЧЕСКАЯ ХАРАКТЕРИСТИКА ИНТАКТ-
НЫХ И КОНТАКТНЫХ КРЫС 
Р.-А.Кийвет, Л.Ряго, Я.Харро, М.Цильмер, 
Т.Вихалемм, К.Цильмер 
Р е з ю м е  
Хроническое стрессирование животных (т.е. контактные 
крысы) проводилось цутем привыкания их к манипуляциям в ус­
ловиях, предшествующих декапитации в течение 10-12 дней. Ин-
тактных крыс держали при стабильных условиях вивария до дня 
опыта. Хроническое стрессирование вызывало уменьшение плот­
ности мест связывания эН-флунитраэепама во фронтальной коре, 
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почках и надпочечниках, уменьшение количества ГАМКд-рецепто-
ров в коре мозга и гиппокампе. Уменьшалась также плотность 
мест связывания 3Н-спжперона во фронтальной коре и плотность 
мест связывания эН-спиперона и эН-дипренорфина в мезолимби-
ческих структурах. Изменения наблюдались также в концентра­
ции диеновых коньюгатов во фронтальной коре и соматотройного 
гормона в крови. В модели поднятого крестообразного лабирин­
та контактные крысы оказывались более тревожными по парамет­
рам исследовательской активности и дефекации. Таким образом, 
наблюдаемые различия в поведении и биохимических параметрах 
между контактам« и штатными животными указывают на более 
выраженное стрессовое состояние контактных крыс. 
ИЗМЕНЕНИЯ В РЕЦЕПТОРАХ ГАЫК И БЕНЗОДИАЗЕПИНОВ ПОСЛЕ 
ЭЛЕКТРОБОЛЕВОГО РАЗДРАЖЕНИЯ У КРЫС -
ВЛИЯНИЕ ДИАЗЕПАМА 
Р.-А.Кийвет, Я.Харро, Л.Ряго, М.Имьд 
Р е з ю м е  
В качестве однократного стрессового воздействия использо­
валась модель электроболевого раздражения в течение 3 мин не­
посредственно перед декапитацией животных. На основании опы­
тов связывания выяснилось, что электроболевое раздражение вы­
зывало уменьшение плотности мест связывания 3Н-флунитразепама 
и 3Н-мусцимола в коре головного мозга и гиппокампе. Уменьша­
лась и плотность периферических мест связывания бензодиазепи­
нов в почках и надпочечниках. При этом одинаковое уменьшение 
наблюдалось у интактных крыс и у крыс, хронически привыкаю­
щих к манипуляциям в условиях, предшествующих декапитации. 
Таким образом, хроническое стрессирование крыс не влияло на 
действие однократного стрессового воздействия на рецепторном 
уровне. Предварительное введение диазепама (2,5 мг/кг) б на­
ших опытах не устраняло эффект электроболевого раздражения 
на рецепторы ГАМК и бензодиазепинов. 
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ФУНКЦИОНАЛЬНАЯ РОЛЬ ДОФАМИНОВЫХ Д1 РЕЦЕПТОРОВ В 
ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЕ 
К.Черешка, А.1арковский 
Р е з ю м е  
В опытах радиолигандного связывания с мембранами мозга 
крыс изучалось связывание избирательного агониста Д1-рецеп-
торов ЭН-СКФ 38393. Установлено, что связывание ЭН-СНФ 38393 
зависит от состава инкубационной среды и температуры инкуба­
ции. Наибольшее отношение специфического связывания к неспе­
цифическому было достигнуто в фосфатном буфере, если инкуба­
ция проводилась при 0°С. Анализ связывания в координатах 
Скэтчарда показал, что 3Н-СН$ 38393 связывается с гомогенной 
популяцией рецепторов с плотностью 384 + 43 фыоль/мг и 
Кд=5,8 + 1,0 нМ. Региональное распределение в переднем мозге 
крыс Д1-рецеп*оров, меченых ЭН-СЮ 38393, соответствовало 
распределению Д2-рецепторов, меченых эН-епипероном. Способ­
ность нейролептиков угнетать связывание 8Н-СКФ 38393 и 3Н-спи-
перона сочиталаеь с их более выраженной способностью вызывать 
каталепсию. Возможно, каталептогенное действие нейролептиков 
связано с блокадой обоих типов дофаминовых рецепторов Д1 и 
да. 
УМЕНЬШЕНИЕ СВЯЗЫВАНИЯ эН-СПИПЕРОНА ™ VIVO в МОЗГЕ 
МЫШЕЙ ПОСЛЕ ХРОНИЧЕСКОГО ПРИМЕНЕНИЯ ГАЛОПЕРВДОЛА 
А.Жарковский, К. Черешка 
Р е з ю м е  
В опытах на мылах введение галоперидола в дозе 2,5 мг/кг 
в/бр приводило к ослаблению угнетающего действия стимулятора 
дофаминовых рецепторов апоморфина (0,1 мг/кг) на локомоцию в 
течение 2-7 дней после отмены галоперидола. Напротив, синд­
ром вертикализации, вызываемый апоморфином в дозе I мг/кг, 
был усилен, что свидетельствовало о повышении чувствительно­
сти постсинаптических дофаминовых рецепторов после отмены га­
лоперидола. Несмотря на признаки гиперчувствительности пост­
синаптических дофаминовых рецепторов, наблюдаемых в поведен­
ческих опытах, у мышей после отмены галоперидола наблюдалось 
уменьшение связывания 3Н-спиперона в стриатуме и мезолимбиче-
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ских структурах в условиях in vivo. Снижение связывания было 
обнаружено и после однократного введения галоперидола. На 
основании этих данных предполагается, что в стадии отмены 
галоперидол в низких концентрациях избирательно блокирует 
пресинаптические дофаминовые рецепторы, с чем, по-видимому, 
связано ослабление пресинаптических эффектов апоморфина и 
уменьшение связывания эН-спиперона 
ВЛИЯНИЕ МИФ НА ПОВЕДЕНЧЕСКИЕ ЭФФЕКТЫ АГОНИСТОВ 
И АНТАГОНИСТОВ ДОФАМИНОВЫХ РЕЦЕПТОРОВ 
К.Черешка, Г.Цеберс, Т.Ээпик, А.Шарковский 
Р е з ю м е  
В опытах на крысах изучалось влияние трипептида (про-
лей-гли, МИФ) на поведенческие и биохимические эффекты аго-
нистов и антагонистов дофаминовых рецепторов. МИФ в дозе 
I мг/кг (в/бр) усиливал угнетающее влияние избирательного 
агониста Д2-рецепторов Ly 171555 (0,01 мг/кг, п.к.) на дви­
гательную активность мышей и провокацию зевательных движе­
ний у крыс. Напротив, ММ не влиял на поведенческие эффек­
ты агониста Д1-рецепторов СКФ 38393. Он не влиял также на 
поведенческие эффекты галоперидола, однако антагонизировал 
действию сульпирида на двигательную активность. На- основании 
этих данных предполагается, что МИФ избирательно повывает 
чувствительность пресинаптических дофаминовых рецепторов Д2 
типа. 
ПАРАМЕТРЫ Х0ЛЕЦИСТ0КИНИН0ВЫХ (ХЦК-8) РЕЦЕПТОРОВ 
В РАЗЛИЧНЫХ СТРУКТУРАХ МОЗГА КРЫС 
А.Соосаар, Э.Васар, А.Ланг 
Р е з ю м е  
Для изучения показателей холецистокининовых (ХЦК-8) ре­
цепторов были проведены опыты связывания с эН-ХЦК-8 в различ­
ных структурах мозга крыс. В опытах ассоциации связывание 
эН-ХЦК-8 достигало равновесия в течение 60-75 мин при 23РС и 
было стабильным в течение 4 часов. Диссоцирование 3Н-ХЦК-8 в 
переднем мозге носило двухфазный характер. Преинкубация мемб­
ран мозга при 37°С ликвидировала более аффинные места свяаы-
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вания. Важно отметить, что преинкубацнл мембран при 37°С не 
изменяла плотность ХЦК-8 рецепторов, а понижала в 1,5-2 раза 
их аффинность. Число мест связывания ХЦК-8 было наивысшим в 
мезолимбических структурах, несколько меньше в стриатуме и 
во фронтальной коре и самым низким - в стволе мозга. Конс­
танты полуингибирования разных лигандов ХЦК-8 рецепторов бы­
ли весьма одинаковыми в различных структурах мозга, различа­
ясь только для ХЦК-4 и проглумида, антагониста ХЦК-8 рецепто­
ров. фи них константы полуингибирования различались 3-4 ра­
за. Цэе инкубация мембран при 37°С не изменяла аффинность 
ХЦК-8 рецепторов для церулеина, аналога ХЦК-8, однако повыша­
ла аффинность для тифлуадома, антагониста ХЦК-8 рецепторов, 
в 1,5-2 раза. Длительное введение галоперидола (0,5 мг/кг в 
день, в течение 15 дней) подопытным животным не привело к ста­
тистически достоверным изменениям в параметрах ХЦК-8 рецеп­
торов. Доведенный анализ свидетельствует о том, что парамет­
ры ХЦК-8 рецепторов в различных структурах мозга весьма раз­
ные. Эти места связывания отличаются как по аффинности к раз­
ным лигандам ХЦК-8 рецепторов, так и по плотности в различных 
структурах мозга. 
ВЗАИМОДЕЙСТВИЕ МЕЖДУ НЕЙРОЛЕПТИКОМ И Х0ЛЕЦИСТ0-
КИНИНОМ: УЧАСТИЕ НАТРИЕВОГО НАСОСА 
Э.Васар, М.Цильмер, А.Соосаар 
Р е з ю м е  
В опытах на белых крысах-самцах было установлено, 
что церулеин (10 мкг/кг), агонист ХЦК-8 рецепторов, и проглу-
мид (I мг/кг), антагонист ХЦК-8, уменьшают активность натрие­
вого насоса в ралзичных структурах мозга. Одновременно приме­
нение церулеина и проглумида полностью подавляло действие 
обоих веществ. Острое введение галоперидола (0,5 мг/кг) умень­
шало активность натриевого насоса, однако после длительного 
введения (в течение 15 дней) наблюдалось заметное усиление 
подавляющего действия галоперидола. Острое или длительное 
введение проглумида полностью антагонизировало действие мно­
гократных введений галоперидола. В опытах радиолигандного свя­
зывания совместное длительное введение галоперидола и проглу­
мида устраняло влияние галоперидола йа связывание эН-ХЦК-8 в 
различных структурах переднего мозга. 1Ъ всей вероятности, 
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пониженная активность натриевого насоса, а также уменьшение 
кооперативности ионов натрия к натриевому насосу находятся 
в основе развития деполяризационной блокады дофаминовых ней­
ронов при введении агоннстов ХЦК-8 * нейролептических ве­
ществ. 
ПОДНЯТЫЙ КРЕСТООБРАЗНЫЙ ЛАБИРИНТ КАК ИНСТРУМЕНТ 
ДЛЯ ИССЛЕДОВАНИЯ СОСТОЯНИЯ ТРЕВОГИ И СТРАХА НА 
ГРЫЗУНАХ 
Я.Харро, Р.-А.Кийвет, М.Шльд, Л.Ряго 
Р е з ю м е  
ШСМ дозозаеиеимо уменьшал поведенческую активность мы­
шей в поднятом крестообразном лабиринте. Диазепам обладал 
противоположным действием. В модели открытого поля оба ве­
щества были эффективны только в дозах, нарушающих базальную 
двигательную активность. 
На основании спонтанной более или менее тревожной иссле­
довательской активности в поднятом крестообразном лабиринте 
животные были разделены на две группы. Показано, что у мышей 
и крыс с более тревожным поведением связывание 3Н-флунитра-
зепама с бензодиазепиновыми рецепторами в коре больших полу­
шарий было более низким, чем у животных с менее тревожным 
поведением. Различий в связывании 3Н-фдунитразепама в моз­
жечке обеих групп обнаружено не было. Обсуждается вопрос о 
возможности использования экспериментов селектирования гры­
зунов в моделях исследовательской активности для выявления 
животных с тревожным состоянием и изучения нейрохимических 
основ этого явления. 
ПРОБЛЕМА АДАПТАЦИИ В ФАРМАКОЛОГИИ 
Л.Нурманд 
Р е з ю м е  
ГЬказано, что адаптивно-компенсаторные реакции возника­
ют на разных уровнях регуляции практически к любому лекарст­
венному веществу. 
На молекулярном-клеточном уровне из подобных реакций 
наиболее изучены изменения чувствительности рецепторов и/или 
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скорости оборота лиганда в ответ на воздействие агонистами 
или антагонистами. На системном уровне к этим реакциям мож­
но отнести индукцию ферментов, компенсаторную активацию 
противоположно действующих систем, подавление секреции гор­
монов в ответ на введение экзогенного гормона и т.д. 
Все эта реакции нередко имеют решающую роль в проявле­
нии и продолжительности действия, а также в возникновении 
побочных реакции и синдрома абстиненции или отмены. Прояв­
ление действия любого лекарственного вещества складывается 
из непосредственных функциональных сдвигов, возникающих в 
результате взаимодействия вещества с рецептором, и адаптив­
но-компенсаторных реакции организма на эти сдвиги. 
Изучение этих реакций особенно важно при оценке дейст­
вия новых лекарственных веществ. Учитывание этих реакций 
имеет также большое значение в формировании мышления врача, 
при выборе рациональных лекарств, тактики и схемы лечения. 
ХРШОФАРМАКОЛОГИЧВСКИЕ АСПЕКТЫ ДЕЙСТВИЯ ФЕНИБУТА 
М.Оттер 
Р е з ю м е  
В опытах на белых мылах, проводимых 4 раза в день 
(06.00, 12.00, 18.00 и 24.00) было выяснено, что в фармако­
логических, биохимических и поведенческих эффектах фенибу-
та появляются суточные вариации. В течение суток депримирую-
щие эффекты фенибута на определенные параметры (исследова­
тельская активность, порог агрессивности, координация дви­
жений) сильнее выражены в полдень (12.00). Что касается 
ноотропных эффектов, то антигипоксический и противосудорож-
ный эффекты сильнее в полночь (24.00), а антиамнестический 
эффект - при низком исходном уровне мнестических способно­
стей. Отрицательные стороны действия фенибута, уменьшение 
продолжительности плавания в воде при ЕРС и летальный эф­
фект самые выраженные в 18.00. Определенную роль в измене­
ниях эффектов фенибута играют суточные колебания содержания 
ДА в стриатуме и цАМФ в крови. 
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